{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "0813a030",
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "from datetime import datetime"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "2ba9929d",
   "metadata": {},
   "outputs": [],
   "source": [
    "data = pd.read_csv('2023_01_04 Master Clintrials Data.csv')\n",
    "syn_data = pd.read_csv(\"2023_03_27_synonyms_ph3.csv\")\n",
    "d_index = pd.read_csv('drug_index.csv')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "b817868e",
   "metadata": {},
   "outputs": [],
   "source": [
    "query_mol = [x for x in set(syn_data['molecule_id'])]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "5135d79b",
   "metadata": {},
   "outputs": [],
   "source": [
    "#getting dates into datetime format for finding min\n",
    "a = list(data['start_date'])\n",
    "\n",
    "for i, x in enumerate(a):\n",
    "    if len(x.split('-')) == 2:\n",
    "        a[i] = '01-'+x\n",
    "\n",
    "data['start_date'] = [datetime.strptime(x, '%d-%b-%y') if x != 'no data' else 'no data' for x in a]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "4c3933b1",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "a9c94309",
   "metadata": {},
   "outputs": [],
   "source": [
    "#this currently prints \"log\" to console, could have this output a .txt file in the future\n",
    "\n",
    "def find_min_phase_dates(data, syn_data, d_index, query_mol):\n",
    "    molecule_list = []\n",
    "    intervention_list = []\n",
    "    nct_id_list = []\n",
    "    title_list = []\n",
    "    phase_list = []\n",
    "    min_start_date_list = []\n",
    "    sponsor_list = []\n",
    "    \n",
    "    \n",
    "    for mol in query_mol:\n",
    "        syns = syn_data['syn'][syn_data['molecule_id'] == mol]\n",
    "        syns = [x.lower() for x in syns]\n",
    "        print('\\n\\nQuerying', syns, 'for ' + mol)\n",
    "        \n",
    "        nct_ids_per_drug = list()\n",
    "        for query_syn in syns:\n",
    "            for intervention in d_index['Intervention']:\n",
    "                if str(query_syn) in str(intervention):\n",
    "                    intv_ids = list(d_index['NCT ID'][d_index['Intervention'] == intervention].values)\n",
    "                    nct_ids_per_drug += intv_ids\n",
    "        print('\\n', len(set(nct_ids_per_drug)), 'Trials found for ' + mol)\n",
    "                \n",
    "        data_per_drug = data[data['nct_id'].isin(set(nct_ids_per_drug))]\n",
    "        \n",
    "        for phase in ['Phase 1', 'Phase 2', 'Phase 3']:\n",
    "            phase_data_per_drug = data_per_drug[data_per_drug['phase'] == phase]\n",
    "            \n",
    "            try:\n",
    "                min_row_per_phase = (phase_data_per_drug[phase_data_per_drug['start_date'] == \n",
    "                                                         phase_data_per_drug['start_date'].min()])\n",
    "                intervention_list.append(min_row_per_phase['intervention_name'].values[0])\n",
    "                nct_id_list.append(min_row_per_phase['nct_id'].values[0])\n",
    "                title_list.append(min_row_per_phase['official_title'].values[0])\n",
    "                phase_list.append(min_row_per_phase['phase'].values[0])\n",
    "                min_start_date_list.append(min_row_per_phase['start_date'].values[0])\n",
    "                sponsor_list.append(min_row_per_phase['sponsors'].values[0])\n",
    "                molecule_list.append(mol)\n",
    "\n",
    "                print('\\n\\nTitle of', phase, 'initial study found:', min_row_per_phase['official_title'].values[0])\n",
    "                print(phase, 'start date:', min_row_per_phase['start_date'].values[0].strftime('%m/%d/%Y'))\n",
    "                print('Interventions for study:', min_row_per_phase['intervention_name'].values[0])\n",
    "                                     \n",
    "            except:\n",
    "                print('\\n No', phase, 'Data found for', mol)\n",
    "    \n",
    "    min_phase_data = pd.DataFrame(columns=['molecule', 'intervention', 'nct_id', 'title', \n",
    "                                           'phase', 'min_start_date', 'sponsor'])\n",
    "    min_phase_data['molecule'] = molecule_list\n",
    "    min_phase_data['intervention'] = intervention_list\n",
    "    min_phase_data['nct_id'] = nct_id_list\n",
    "    min_phase_data['title'] = title_list\n",
    "    min_phase_data['phase'] = phase_list\n",
    "    min_phase_data['min_start_date'] = min_start_date_list\n",
    "    min_phase_data['sponsor'] = sponsor_list\n",
    "    \n",
    "    return min_phase_data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "6115bcef",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\n",
      "Querying ['ozanimod', '986374', 'rpc-1063', 'rpc1063', 'rpc 1063', 'zeposia'] for Zeposia\n",
      "\n",
      " 34 Trials found for Zeposia\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Phase I, Multicenter, Randomized, 12-Week, Open-Label Study to Evaluate the Multiple Dose Pharmacokinetics and Pharmacodynamics of RPC 1063 in Patients With Relapsing Multiple Sclerosis\n",
      "Phase 1 start date: 06/23/2016\n",
      "Interventions for study: RPC1063\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo Controlled Parallel-Group Study to Evaluate the Clinical Efficacy and Safety of Induction Therapy With RPC1063 in Patients With Moderately to Severely Active Ulcerative Colitis\n",
      "Phase 2 start date: 12/26/2012\n",
      "Interventions for study: Ozanimod; Placebo\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients\n",
      "Phase 3 start date: 12/03/2013\n",
      "Interventions for study: Interferon beta-1a; Interferon beta-1a placebo; Ozanimod; Ozanimod placebo\n",
      "\n",
      "\n",
      "Querying ['amivantamab', 'cnto-4424', 'jnj611', 'jnj-611', 'jnj 611', 'cnto 4424', 'cnto4424', 'ami-lc-md', 'amivantamab admixed with rhuph20', 'jnj 372', 'jnj372', 'jnj-372', 'jnj-6372', 'jnj6372', 'jnj 6372', 'rybrevant'] for Rybrevant\n",
      "\n",
      " 22 Trials found for Rybrevant\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose, Interventional Study of JNJ-61178104 in Healthy Subjects\n",
      "Phase 1 start date: 04/01/2016\n",
      "Interventions for study: JNJ-61178104 Intravenous; JNJ-61178104 Subcutaneous; Placebo\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: A Phase 2, Open-label Study of Amivantamab in Subjects With Previously Treated Advanced or Metastatic Gastric or Esophageal Cancer\n",
      "Phase 2 start date: 08/30/2021\n",
      "Interventions for study: Amivantamab\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.\n",
      "Phase 3 start date: 09/30/2020\n",
      "Interventions for study: Amivantamab; Lazertinib; Osimertinib; Placebo\n",
      "\n",
      "\n",
      "Querying ['ixekizumab', 'ly 2439821', 'ly-2439821', 'ly2439821', 'taltz'] for Taltz\n",
      "\n",
      " 50 Trials found for Taltz\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: Multiple-Dose, Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY2439821 in Japanese Patients With Rheumatoid Arthritis on Concomitant Methotrexate Treatment\n",
      "Phase 1 start date: 05/01/2010\n",
      "Interventions for study: LY2439821; Placebo\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: A Phase 2 Dose-Ranging Study of Multiple Subcutaneous Doses of LY2439821 (an Anti-IL-17 Antibody) in Patients With Active Rheumatoid Arthritis on Concomitant DMARD Therapy\n",
      "Phase 2 start date: 08/01/2009\n",
      "Interventions for study: LY2439821; Placebo\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis\n",
      "Phase 3 start date: 11/16/2011\n",
      "Interventions for study: 80 mg Ixekizumab Dosing Regimens 1, 2, and 3; Placebo\n",
      "\n",
      "\n",
      "Querying ['cariprazine', 'mp-214', 'rgh-188', 'mp214', 'rgh188', 'mp 214', 'rgh 188', 'symvenu', 'vraylar', 'wid-rgc20', 'widrgc20', 'wid rgc20', 'reagila'] for Reagila\n",
      "\n",
      " 45 Trials found for Reagila\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: Evaluation of the Effects of Sequential Multiple-Dose Regimens of Cariprazine on Cardiac Repolarization in Patients With Schizophrenia\n",
      "Phase 1 start date: 06/01/2011\n",
      "Interventions for study: Cariprazine; Risperidone/Moxifloxacin\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of RGH-188 in the Acute Exacerbation of Schizophrenia\n",
      "Phase 2 start date: 11/01/2006\n",
      "Interventions for study: RGH-188\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Double-Blind, Placebo-Controlled, Evaluation of the Safety and Efficacy of Cariprazine in Patients With Acute Mania Associated With Bipolar I Disorder\n",
      "Phase 3 start date: 02/01/2010\n",
      "Interventions for study: Cariprazine; Placebo\n",
      "\n",
      "\n",
      "Querying ['eluxadoline', 'jnj 27018966', 'jnj-27018966', 'jnj27018966', 'truberzi', 'viberzi'] for Viberzi\n",
      "\n",
      " 9 Trials found for Viberzi\n",
      "\n",
      " No Phase 1 Data found for Viberzi\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: A Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose Ranging, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Irritable Bowel Syndrome With Diarrhea\n",
      "Phase 2 start date: 04/28/2010\n",
      "Interventions for study: Eluxadoline; Placebo\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome\n",
      "Phase 3 start date: 05/29/2012\n",
      "Interventions for study: Eluxadoline; Placebo\n",
      "\n",
      "\n",
      "Querying ['belzutifan', 'mk 6482', 'mk-6482', 'mk6482', 'pt 2977', 'pt-2977', 'pt2977', 'who 11196', 'who-11196', 'who11196', 'welireg'] for Welireg\n",
      "\n",
      " 19 Trials found for Welireg\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Phase 1, Dose-Escalation and Expansion Trial of PT2977, a HIF-2α Inhibitor, in Patients With Advanced Solid Tumors\n",
      "Phase 1 start date: 12/07/2016\n",
      "Interventions for study: Belzutifan\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: An Open-Label Phase 2 Study to Evaluate PT2977 for the Treatment of Von Hippel Lindau Disease-Associated Renal Cell Carcinoma\n",
      "Phase 2 start date: 05/02/2018\n",
      "Interventions for study: Belzutifan\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants With Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1/L1 and VEGF-Targeted Therapies\n",
      "Phase 3 start date: 02/27/2020\n",
      "Interventions for study: Belzutifan; Everolimus\n",
      "\n",
      "\n",
      "Querying ['ceftolozane/tazobactam', 'tazobactam/ceftolozane', 'mk-7625a', 'mk7625a', 'mk 7625a', 'cxa-201', 'cxa201', 'cxa 201', 'cxa-101/tazobactam', 'tazobactam/cxa-101', 'zerbaxa'] for Zerbaxa\n",
      "\n",
      " 21 Trials found for Zerbaxa\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Double-Blind, Double-Dummy, Randomized, Moxifloxacin and Placebo Controlled, Four-Way Crossover Study of the Effects of a Single Intravenous Supra-Therapeutic Dose and Single Intravenous Therapeutic Dose of CXA-101/Tazobactam on the QT/QTC Intervals in Healthy Subjects\n",
      "Phase 1 start date: 06/01/2010\n",
      "Interventions for study: CXA-101/tazobactam; Moxifloxacin; placebo\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: A Phase 2, Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial to Study the Safety and Efficacy of Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem in Pediatric Subjects With Complicated Intra-Abdominal Infection\n",
      "Phase 2 start date: 04/03/2018\n",
      "Interventions for study: Ceftolozane/Tazobactam; Meropenem; Metronidazole; Placebo for Metronidazole\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Multicenter, Double-Blind, Randomized, Phase 3 Study to Compare the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis\n",
      "Phase 3 start date: 06/20/2011\n",
      "Interventions for study: CXA-201; Levofloxacin\n",
      "\n",
      "\n",
      "Querying ['upadacitinib', 'abt 494', 'abt-494', 'abt494', 'rinvoq'] for Rinvoq\n",
      "\n",
      " 52 Trials found for Rinvoq\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Study in Healthy Adult Volunteers and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability, and Pharmacokinetics After Multiple Dosing of ABT-494\n",
      "Phase 1 start date: 11/01/2012\n",
      "Interventions for study: ABT-494; Placebo; Tofacitinib\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Investigate the Safety and Efficacy of ABT-494 Given With Methotrexate (MTX) in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Who Have Had an Inadequate Response or Intolerance to Anti-TNF Biologic Therapy\n",
      "Phase 2 start date: 10/01/2013\n",
      "Interventions for study: ABT-494; Placebo\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Background of Methotrexate (MTX) and Who Have an Inadequate Response to MTX (MTX-IR)\n",
      "Phase 3 start date: 12/01/2015\n",
      "Interventions for study: Adalimumab; Placebo for Adalimumab; Placebo for Upadacitinib; Upadacitinib\n",
      "\n",
      "\n",
      "Querying ['selpercatinib', 'loxo292', 'loxo 292', 'loxo-292', 'ly-3527723', 'ly3527723', 'who 10967', 'ly 3527723', 'retsevmo', 'retevmo'] for Retevmo\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " 28 Trials found for Retevmo\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A 2-Part, Open-Label, Fixed-Sequence Study to Evaluate the Effects of Multiple Doses of Itraconazole and Rifampin on the Single-Dose Pharmacokinetics of LOXO-292 in Healthy Adult Subjects\n",
      "Phase 1 start date: 05/11/2018\n",
      "Interventions for study: Itraconazole; Rifampin; Selpercatinib\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol\n",
      "Phase 2 start date: 07/24/2017\n",
      "Interventions for study: Biopsy; Biospecimen Collection; Ensartinib; Erdafitinib; Laboratory Biomarker Analysis; Larotrectinib Sulfate; Mutation Carrier Screening; Olaparib; Palbociclib; Pharmacological Study; Samotolisib; Selpercatinib; Selumetinib Sulfate; Tazemetostat; Tipifarnib; Ulixertinib; Vemurafenib\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)\n",
      "Phase 3 start date: 02/11/2020\n",
      "Interventions for study: Cabozantinib; Selpercatinib; Vandetanib\n",
      "\n",
      "\n",
      "Querying ['asciminib', 'stamp inhibitor', 'abl-001', 'abl001', 'scemblix'] for Scemblix\n",
      "\n",
      " 24 Trials found for Scemblix\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Phase I, Multicenter, Open-label Study of Oral ABL001 in Patients With Chronic Myelogenous Leukemia (CML) or Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL)\n",
      "Phase 1 start date: 04/24/2014\n",
      "Interventions for study: ABL001; ABL001 + Nilotinib; ABL001+dasatinib; ABL001+imatinib\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: A Phase 2, Multi-center, Open-label, Randomized Study of Oral Asciminib Added to Imatinib Versus Continued Imatinib Versus Switch to Nilotinib in Patients With CML-CP Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response\n",
      "Phase 2 start date: 11/22/2018\n",
      "Interventions for study: Asciminib add-on; Asciminib single agent; Imatinib; Nilotinib\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Phase 3, Multi-center, Open-label, Randomized Study of Oral ABL001 Versus Bosutinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated With 2 or More Tyrosine Kinase Inhibitors\n",
      "Phase 3 start date: 10/26/2017\n",
      "Interventions for study: Asciminib; Bosutinib\n",
      "\n",
      "\n",
      "Querying ['tofacitinib', 'cp 690', 'cp-690', 'cp690', 'xeljanz'] for Xeljanz\n",
      "\n",
      " 186 Trials found for Xeljanz\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: Phase 1, Investigator-Blind, Subject-Blind, Sponsor-Open, Placebo-Controlled, Two-Week, Multiple Dose Escalation Study In Medically Stable Subjects With Psoriasis To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of CP-690,550\n",
      "Phase 1 start date: 11/01/2002\n",
      "Interventions for study: tofacitinib\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Compare 3 Dose Levels Of CP-690,550 Versus Placebo, Administered Orally Twice Daily (BID) For 6 Weeks, In The Treatment Of The Signs And Symptoms Of Subjects With Active Rheumatoid Arthritis\n",
      "Phase 2 start date: 01/01/2005\n",
      "Interventions for study: CP-690,550; Placebo\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Long-term, Open-label Follow-up Study Of Tofacitinib (Cp-690,550) For Treatment Of Rheumatoid Arthritis\n",
      "Phase 3 start date: 02/05/2007\n",
      "Interventions for study: CP-690,550\n",
      "\n",
      "\n",
      "Querying ['lasmiditan', 'col144', 'col 144', 'col-144', 'ly-573144', 'ly573144', 'ly 573144', 'rayvow', 'reyvow'] for Reyvow\n",
      "\n",
      " 32 Trials found for Reyvow\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Randomized, Double-blind, Placebo-controlled, 4-way Crossover Study to Compare the Effects on the Cardiac De- and Repolarization Duration as Well as Other Cardiac Safety Parameters of Two Doses of Oral Lasmiditan (100 mg and 400 mg) With Those of Moxifloxacin (400 mg) and Placebo in Healthy Subjects\n",
      "Phase 1 start date: 09/16/2011\n",
      "Interventions for study: Lasmiditan; Moxifloxacin; Placebo\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: A Placebo-Controlled, Group Sequential, Adaptive Treatment Assignment Study of Intravenous COL-144 (LY573144) in the Acute Treatment of Migraine\n",
      "Phase 2 start date: 11/01/2006\n",
      "Interventions for study: Lasmiditan; Placebo\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study\n",
      "Phase 3 start date: 04/01/2015\n",
      "Interventions for study: Lasmiditan 100 mg; Lasmiditan 200 mg; Placebo (matches lasmiditan doses)\n",
      "\n",
      "\n",
      "Querying ['pazopanib', 'armala', '78603', 'votrient'] for Votrient\n",
      "\n",
      " 261 Trials found for Votrient\n",
      "\n",
      " No Phase 1 Data found for Votrient\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: A Phase II, Open-Label Study of Pazopanib (GW786034) in Patients With Relapsed or Refractory Multiple Myeloma\n",
      "Phase 2 start date: 01/01/2005\n",
      "Interventions for study: GW786034\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Randomised, Double-blind, Placebo Controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) Compared to Placebo in Patients With Locally Advanced and/or Metastatic Renal Cell Carcinoma\n",
      "Phase 3 start date: 04/01/2006\n",
      "Interventions for study: Pazopanib; placebo\n",
      "\n",
      "\n",
      "Querying ['sotrovimab', 'gsk-4182136', 'gsk4182136', 'gsk 4182136', 'vir-7831', 'vir7831', 'vir 7831', 'wbp 2275', 'wbp-2275', 'wbp2275', 'xevudy'] for Xevudy\n",
      "\n",
      " 21 Trials found for Xevudy\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Phase I, Single-blind, Randomized, Single-dose Clinical Pharmacology Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Sotrovimab vs Placebo by Intravenous or Intramuscular Administration in Healthy Japanese and Caucasian Participants\n",
      "Phase 1 start date: 07/06/2021\n",
      "Interventions for study: Placebo to Biologic; sotrovimab\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)\n",
      "Phase 2 start date: 10/29/2020\n",
      "Interventions for study: Bamlanivimab; Bebtelovimab; Etesevimab; Placebo; VIR-7831\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients With COVID-19\n",
      "Phase 3 start date: 08/04/2020\n",
      "Interventions for study: AZD7442; BRII-196/BRII-198; LY3819253; MP0420; PF-07304814; Placebo; Remdesivir; VIR-7831\n",
      "\n",
      "\n",
      "Querying ['sarecycline', 'wc-3035', 'wc3035', 'wc 3035', 'p 005672', 'p005672', 'p-005672', 'p 0005672', 'p0005672', 'p-0005672', 'seysara'] for Seysara\n",
      "\n",
      " 7 Trials found for Seysara\n",
      "\n",
      " No Phase 1 Data found for Seysara\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 3 Different Doses of a Novel Tetracycline Compared to Placebo in the Treatment of Facial Acne Vulgaris, Study PR-10411\n",
      "Phase 2 start date: 06/30/2012\n",
      "Interventions for study: 100 mg P005672-HCl; 50 mg P005672-HCl; Placebo\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of 1.5 mg/kg Per Day of Sarecycline Compared to Placebo in the Treatment of Acne Vulgaris\n",
      "Phase 3 start date: 12/03/2014\n",
      "Interventions for study: Placebo; Sarecycline\n",
      "\n",
      "\n",
      "Querying ['enfortumab', 'ags-m6', 'ags-22c', 'ags-22m', 'asg-22c', 'asg-22m', 'ags22c', 'ags22m', 'asg22c', 'asg22m', 'ags 22c', 'ags 22m', 'asg 22c', 'asg 22m', 'padcev'] for Padcev\n",
      "\n",
      " 24 Trials found for Padcev\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of AGS-22M6E or ASG-22CE Given as Monotherapy Followed by Expansion Cohorts in Subjects With Malignant Solid Tumors That Express Nectin-4\n",
      "Phase 1 start date: 06/01/2011\n",
      "Interventions for study: AGS-22M6E; ASG-22CE\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: A Single-arm, Open-label, Multicenter Study of Enfortumab Vedotin (ASG-22CE) for Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Immune Checkpoint Inhibitor (CPI) Therapy\n",
      "Phase 2 start date: 10/08/2017\n",
      "Interventions for study: Enfortumab vedotin\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or Who Refuse Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer (VOLGA)\n",
      "Phase 3 start date: 10/20/2017\n",
      "Interventions for study: Durvalumab; Enfortumab Vedotin; Radical Cystectomy; Tremelimumab\n",
      "\n",
      "\n",
      "Querying ['luspatercept', 'ace-536', 'ace536', 'ace 536', 'bms-986346', 'bms 986346', 'bms986346', 'reblozyl'] for Reblozyl\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " 24 Trials found for Reblozyl\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of ACE-536 in Healthy Postmenopausal Women\n",
      "Phase 1 start date: 09/01/2011\n",
      "Interventions for study: ACE-536; Placebo\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: A Phase 2, Open Label, Ascending Dose Study of ACE-536 for the Treatment of Anemia in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)\n",
      "Phase 2 start date: 01/01/2013\n",
      "Interventions for study: ACE-536\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo for the Treatment of Anemia Due to the IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Subjects With Ring Sideroblasts Who Require Red Blood Cell Transfusions.\n",
      "Phase 3 start date: 02/09/2016\n",
      "Interventions for study: Luspatercept; Placebo\n",
      "\n",
      "\n",
      "Querying ['rg 6152', 'rg-6152', 'rg6152', 'baloxavir', '33188', 'xofluza'] for Xofluza\n",
      "\n",
      " 12 Trials found for Xofluza\n",
      "\n",
      " No Phase 1 Data found for Xofluza\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: Efficacy of Combination Baloxovir and Oseltamivir Therapy in Influenza Infected Immunocompromised Hosts\n",
      "Phase 2 start date: 10/11/2021\n",
      "Interventions for study: Baloxavir Marboxil; Oseltamivir\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza\n",
      "Phase 3 start date: 12/08/2016\n",
      "Interventions for study: Baloxavir Marboxil; Oseltamivir; Placebo to Baloxavir Marboxil; Placebo to Oseltamivir\n",
      "\n",
      "\n",
      "Querying ['elagolix', 'abt 620', 'nbi 56418', 'abt620', 'nbi56418', 'abt-620', 'nbi-56418', 'oriahnn', 'orilissa'] for Orilissa\n",
      "\n",
      " 29 Trials found for Orilissa\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Phase 1, Open-Label Study of the Effects of Elagolix on Ovarian Activity, Ovulation and Ovarian Reserve in Premenopausal Females\n",
      "Phase 1 start date: 06/01/2011\n",
      "Interventions for study: Elagolix; elagolix\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of NBI-56418 in Endometriosis\n",
      "Phase 2 start date: 04/01/2005\n",
      "Interventions for study: NBI-56418 (GnRH antagonist); placebo\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain\n",
      "Phase 3 start date: 05/22/2012\n",
      "Interventions for study: elagolix; placebo\n",
      "\n",
      "\n",
      "Querying ['insulin glargine', 'hoe 71gt', 'hoe 901', 'hoe-71gt', 'hoe-901', 'ly 2963016', 'ly-2963016', 'ly2963016', 'mk-1293', 'myl-1501d', 'mk 1293', 'myl 1501d', 'mk1293', 'myl1501d', 'hoe71gt', 'hoe901', 'toujeo'] for Toujeo\n",
      "\n",
      " 420 Trials found for Toujeo\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: Assessment of Safety and Tolerability of Lantus® (Insulin Glargine) in Subjects With Impaired Fasting Glucose (IFG) or Impaired Glucose Tolerance (IGT)\n",
      "Phase 1 start date: 02/01/2002\n",
      "Interventions for study: Lantus® (insulin glargine)\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: Effects of Colesevelam on Insulin Sensitivity in Type 2 Diabetes Mellitus\n",
      "Phase 2 start date: 06/01/2005\n",
      "Interventions for study: Colesevelam; Colesevelam matching placebo; Insulin glargine (Lantus)\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: Target Glycemic Control and the Incidence of Symptomatic Nocturnal Hypoglycemia in Insulin Naïve Subjects With Type 2 Diabetes on Oral Hypoglycemic Agent(s) and Treated With Insulin Glargine or NPH Human Insulin.\n",
      "Phase 3 start date: 01/01/2000\n",
      "Interventions for study: NPH human insulin; insulin glargine\n",
      "\n",
      "\n",
      "Querying ['crizotinib', '2341066', 'pf-1066', 'pf 1066', 'pf1066', 'xalkori'] for Xalkori\n",
      "\n",
      " 107 Trials found for Xalkori\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: PHASE 1 SAFETY, PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF PF-02341066, A MET/HGFR SELECTIVE TYROSINE KINASE INHIBITOR, ADMINISTERED ORALLY TO PATIENTS WITH ADVANCED CANCER\n",
      "Phase 1 start date: 04/19/2006\n",
      "Interventions for study: Itraconazole; PF-02341066; Rifampin\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: Phase 2, Open-label Single Arm Study Of The Efficacy And Safety Of Pf-02341066 In Patients With Advanced Non-small Cell Lung Cancer (Nsclc) Harboring A Translocation Or Inversion Involving The Anaplastic Lymphoma Kinase (Alk) Gene Locus\n",
      "Phase 2 start date: 01/01/2010\n",
      "Interventions for study: PF-02341066\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: Phase 3, Randomized, Open-label Study Of The Efficacy And Safety Of Pf-02341066 Versus Standard Of Care Chemotherapy (Pemetrexed Or Docetaxel) In Patients With Advanced Non-small Cell Lung Cancer (Nsclc) Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (Alk) Gene Locus\n",
      "Phase 3 start date: 09/01/2009\n",
      "Interventions for study: Docetaxel; PF-02341066; Pemetrexed\n",
      "\n",
      "\n",
      "Querying ['elbasvir/grazoprevir', 'grazoprevir/elbasvir', 'mk-5172/mk-8742', 'mk-8742/mk-5172', 'mk5172/mk8742', 'mk8742/mk5172', 'mk 5172/mk 8742', 'mk 8742/mk 5172', 'zepatier'] for Zepatier\n",
      "\n",
      " 38 Trials found for Zepatier\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: Bioequivalence Study of CRUshed ElbaSvir/GrAzoprevir compareD to the wholE Tablet (CRUSADE-2)/Hep-NED005\n",
      "Phase 1 start date: 03/28/2019\n",
      "Interventions for study: Zepatier crushed tablet; Zepatier whole tablet\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: A Phase II Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172, MK-8742, and Sofosbuvir in Treatment-Naïve Subjects With Chronic HCV GT1 or GT3 Infection\n",
      "Phase 2 start date: 06/13/2014\n",
      "Interventions for study: Grazoprevir/Elbasvir FDC; Sofosbuvir\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Phase III, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 Versus Boceprevir/Pegylated Interferon/Ribavirin (PR) in Treatment-Naïve and PR Prior Treatment Failure Subjects With Chronic HCV GT1 Infection\n",
      "Phase 3 start date: 11/01/2014\n",
      "Interventions for study: Boceprevir; Grazoprevir/Elbasvir; PegIntron; Ribavarin\n",
      "\n",
      "\n",
      "Querying ['tafluprost', 'afp-168', 'mk-2452', 'afp168', 'mk2452', 'afp 168', 'mk 2452', 'de-085', 'de085', 'de 085', 'de-118', 'de118', 'de 118', 'saflutan', 'taflotan', 'tapros', 'zioptan'] for Zioptan\n",
      "\n",
      " 33 Trials found for Zioptan\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Phase I, Randomized, Double-masked, 3-period Cross-over Clinical Study to Compare the Pharmacokinetics, Safety and Tolerability of the Preservative-free Fixed Dose Combination of Tafluprost 0.0015% and Timolol 0.5% Eye Drops to Those of Preservative-free Tafluprost 0.0015% and Timolol 0.5% Eye Drops in Healthy Volunteers\n",
      "Phase 1 start date: 09/01/2011\n",
      "Interventions for study: Preservative free FDC of tafluprost 0.0015% and timolol 0.5% eye drops; Preservative free tafluprost 0.0015% eye drops; Preservative free timolol 0.5% eye drops\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: A Two-Part Pharmacodynamic Study to Compare VentaProst (Epoprostenol Solution for Inhalation Via Custom Drug Delivery System) Dosing to Conventionally Administered Aerosolized Epoprostenol Dosing in Cardiac Surgery Patients\n",
      "Phase 2 start date: 08/23/2017\n",
      "Interventions for study: VentaProst\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: Pharmacodynamics of Tafluprost 0.0015% Eye Drops: a Comparison Between the Preserved and Unpreserved Formulation in Patients With Open-angle Glaucoma or Ocular Hypertension\n",
      "Phase 3 start date: 09/01/2005\n",
      "Interventions for study: Tafluprost 0.0015%\n",
      "\n",
      "\n",
      "Querying ['ntbc', 'nitisinone', 'sc 0735', 'sc-0735', 'sc0735', 'syn-118', 'syn118', 'syn 118', 'orfadin'] for Orfadin\n",
      "\n",
      " 18 Trials found for Orfadin\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Study to Evaluate the Bioequivalence of Orfadin Suspension 4 mg/mL Compared to Orfadin Capsules 10 mg, and the Effect of Food on the Bioavailability of the Suspension. An Open-label, Randomized, Cross-over, Single-dose Study in Healthy Volunteers\n",
      "Phase 1 start date: 08/01/2012\n",
      "Interventions for study: Nitisinone, capsule; Nitisinone, suspension\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: no data\n",
      "Phase 2 start date: 11/01/1994\n",
      "Interventions for study: NTBC\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: An International, Multicentre, Randomised, Evaluator-blind, No-treatment Controlled, Parallel-group Study to Assess the Efficacy and Safety of Once Daily Nitisinone in Patients With Alkaptonuria After 12 Months of Treatment, Followed by an Additional 36 Month Treatment Period.\n",
      "Phase 3 start date: 04/01/2014\n",
      "Interventions for study: Nitisinone\n",
      "\n",
      "\n",
      "Querying ['fesoterodine', '695838', 'spm 007', 'spm007', 'spm-007', 'spm 907', 'spm907', 'spm-907', 'toviaz'] for Toviaz\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " 64 Trials found for Toviaz\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Phase 1, Open-Label, Randomized, Single-Dose, 2-Cohort, 3-Way Crossover Study To Determine Bioequivalence Of 4 Mg And 8 Mg Fesoterodine SR Tablet Of Commercial Formulation And 8 Mg Fesoterodine SR Tablet Between Formulation E(1) And Formulation F And Investigate Food Effect On Commercial Formulation In Healthy Subjects.\n",
      "Phase 1 start date: 10/01/2008\n",
      "Interventions for study: Fesoterodine\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: Two Phase Extension Trial of SP668 to Investigate the Safety and Tolerability of Sustained Release Fesoterodine in Subjects With Overactive Bladder(OAB): a Double-Blind Phase Followed by an Open-Label Extension Phase\n",
      "Phase 2 start date: 06/01/2003\n",
      "Interventions for study: SPM 907\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Phase 3, Parallel Group, Randomized, Double-Blind, Placebo Controlled Multicenter Trial to Investigate the Efficacy, Tolerability and Safety of Fesoterodine Sustained Release in Subjects With Overactive Bladder Syndrome\n",
      "Phase 3 start date: 10/01/2003\n",
      "Interventions for study: SPM 907\n",
      "\n",
      "\n",
      "Querying ['atogepant', 'agn-241689', 'mk-8031', 'agn241689', 'mk8031', 'agn 241689', 'mk 8031', 'qulipta'] for Qulipta\n",
      "\n",
      " 12 Trials found for Qulipta\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Phase 1b, Open-label, Fixed-sequence, Safety, Tolerability and Drug-drug Interaction Study Between Atogepant and Ubrogepant in Participants With a History of Migraine\n",
      "Phase 1 start date: 03/17/2021\n",
      "Interventions for study: Atogepant; Ubrogepant\n",
      "\n",
      " No Phase 2 Data found for Qulipta\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine\n",
      "Phase 3 start date: 10/08/2018\n",
      "Interventions for study: Atogepant; Standard of Care (SOC) Migraine Preventive Medication\n",
      "\n",
      "\n",
      "Querying ['rxdx-101', 'rxdx101', 'rxdx 101', 'entrectinib', 'nms-e628', 'nmse628', 'nms e628', 'rg 6268', 'rg-6268', 'rg6268', 'rxdx-101', 'rxdx 101', 'rxdx101', 'rozlytrek'] for Rozlytrek\n",
      "\n",
      " 28 Trials found for Rozlytrek\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Phase 1, Multicenter, Open-Label Study of Oral Entrectinib (RXDX-101) in Adult Patients With Locally Advanced or Metastatic Cancer Confirmed to be Positive for NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations\n",
      "Phase 1 start date: 07/28/2014\n",
      "Interventions for study: Entrectinib\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: A Phase II Trial of Targeted Kinase Fusion Inhibition in Unresectable Stage III/IV BRAF/NRAS Wild-Type Melanoma\n",
      "Phase 2 start date: 03/26/2015\n",
      "Interventions for study: Capmatinib; Ceritinib; Entrectinib; Laboratory Biomarker Analysis; Regorafenib\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: Randomized, Open Label, Multicenter, Phase III Study of Entrectinib Versus Crizotinib in Patients With Locally-Advanced or Metastatic Non-Small Cell Lung Cancer Harboring ROS1 Gene Rearrangements With and Without Central Nervous System Metastases\n",
      "Phase 3 start date: 09/30/2021\n",
      "Interventions for study: Crizotinib; Entrectinib\n",
      "\n",
      "\n",
      "Querying ['ipilimumab', 'ctla-4', 'bms-734016', 'bms734016', 'bms 734016', 'mdx-010', 'mdx-101', 'mdx010', 'mdx101', 'mdx 010', 'mdx 101', 'yervoy'] for Yervoy\n",
      "\n",
      " 698 Trials found for Yervoy\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: An Open-label Study Of MDX-CTLA4 In Combination With Tyrosinase/gp100/MART-1 Peptides Emulsified With Montanide ISA 51 In The Treatment Of Patients With Resected Stage III Or Stage IV Melanoma\n",
      "Phase 1 start date: 10/01/2001\n",
      "Interventions for study: MART-1 antigen; adjuvant therapy; gp100 antigen; incomplete Freund's adjuvant; ipilimumab; tyrosinase peptide\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: An Open-label Study Of MDX-010 In Combination With gp100 Peptides Emulsified With Montanide ISA 51 In The Treatment Of Patients With Stage IV Melanoma\n",
      "Phase 2 start date: 01/01/2002\n",
      "Interventions for study: gp100 antigen; incomplete Freund's adjuvant; ipilimumab\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination With a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2*0201-Positive Patients With Previously Treated Unresectable Stage III or IV Melanoma\n",
      "Phase 3 start date: 09/01/2004\n",
      "Interventions for study: MDX-010 (anti-CTLA4) monoclonal antibody; MDX-1379 (gp100) Melanoma Peptide Vaccine\n",
      "\n",
      "\n",
      "Querying ['gs-7977', 'gs7977', 'gs 7977', 'hepcinat', 'hepcvir', 'sofosbuvir', 'p-7977', 'p7977', 'p 7977', 'psi-7977', 'psi7977', 'psi 7977', 'sovihep', 'sovaldi'] for Sovaldi\n",
      "\n",
      " 219 Trials found for Sovaldi\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: An Open-Label Study to Characterize the Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses of PSI-7977 or PSI-352938 in HCV-infected Subjects With Varying Degrees of Hepatic Impairment\n",
      "Phase 1 start date: 07/01/2011\n",
      "Interventions for study: PSI-352938; PSI-7977\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: A Multi-center, Double-Blind, Parallel Group, Randomized, Placebo-Controlled, Dose Ranging Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Oral Administration of PSI-7977 in Combination With Standard of Care (Pegylated Interferon and Ribavirin) in Treatment-Naïve Patients With Chronic HCV Infection Genotype 1\n",
      "Phase 2 start date: 01/01/2010\n",
      "Interventions for study: PEG; Placebo; RBV; Sofosbuvir\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Phase 3, Multicenter, Randomized, Active-Controlled Study to Investigate the Safety and Efficacy of PSI-7977 and Ribavirin for 12 Weeks Compared to Pegylated Interferon and Ribavirin for 24 Weeks in Treatment-Naïve Patients With Chronic Genotype 2 or 3 HCV Infection\n",
      "Phase 3 start date: 12/01/2011\n",
      "Interventions for study: PEG; RBV; Sofosbuvir\n",
      "\n",
      "\n",
      "Querying ['ubrogepant', 'mk-1602', 'mk1602', 'mk 1602', 'ubrelvy'] for Ubrelvy\n",
      "\n",
      " 13 Trials found for Ubrelvy\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Phase 1b, Two-Part, Open-Label, Fixed-Sequence, Safety, Tolerability and Drug-Drug Interaction Study Between Single Dose Erenumab or Galcanezumab and Multiple Dose Ubrogepant in Participants With Migraine\n",
      "Phase 1 start date: 09/26/2019\n",
      "Interventions for study: Erenumab; Galcanezumab; Ubrogepant\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of MK-1602 in the Treatment of Acute Migraine\n",
      "Phase 2 start date: 07/01/2012\n",
      "Interventions for study: MK-1602; Placebo-matching MK-1602; Rescue medication\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine\n",
      "Phase 3 start date: 07/22/2016\n",
      "Interventions for study: Placebo-matching Ubrogepant; Ubrogepant\n",
      "\n",
      "\n",
      "Querying ['trabectedin', 'et-743', 'nsc 684766', 'nsc-648766', 'nsc648766', 'et743', 'et 743', 'ecteinascidin', 'yondelis'] for Yondelis\n",
      "\n",
      " 89 Trials found for Yondelis\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: PHASE I CLINICAL AND PHARMACOKINETIC STUDY TO DETERMINE THE SAFETY OF ECTEINASCIDIN-743 (ET-743) ADMINISTERED AS A SINGLE INTRAVENOUS INFUSION OVER 60 MINUTES EVERY 21 DAYS IN PATIENTS WITH SOLID TUMORS\n",
      "Phase 1 start date: 02/01/1996\n",
      "Interventions for study: trabectedin\n",
      "\n",
      " No Phase 2 Data found for Yondelis\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: An Open-Label Multicenter Randomized Phase 3 Study Comparing the Combination of DOXIL/CAELYX and YONDELIS With DOXIL/CAELYX Alone in Subjects With Advanced Relapsed Ovarian Cancer\n",
      "Phase 3 start date: 04/01/2005\n",
      "Interventions for study: DOXIL; Dexamethasone; Trabectedin\n",
      "\n",
      "\n",
      "Querying ['viokase', 'pancrelipase', 'viokace'] for Viokace\n",
      "\n",
      " 24 Trials found for Viokace\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Single-Dose, Open-Label, Randomized, Crossover Study to Evaluate Intraduodenal Enzyme Delivery of PANCREASE MT in Subjects With Severe Exocrine Pancreatic Insufficiency\n",
      "Phase 1 start date: 07/01/2008\n",
      "Interventions for study: Ensure Plus; Pancrelipase in combination with Ensure Plus\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: A Phase II, Randomized, Investigator-Blinded, Parallel-Group, Pilot Study Evaluating the Safety, Palatability and Effectiveness of Four Doses of Pancrelipase Microtablets in the Treatment of Infants and Toddlers With Cystic Fibrosis-Related Pancreatic Insufficiency and Fat Malabsorption\n",
      "Phase 2 start date: 07/01/2005\n",
      "Interventions for study: Pancrelipase microtablets\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: no data\n",
      "Phase 3 start date: 01/01/2000\n",
      "Interventions for study: Pancrelipase (Creon) 2 tablets with each meal\n",
      "\n",
      "\n",
      "Querying ['risankizumab', 'abbv 066', 'abbv066', 'abbv-066', 'bi-655066', 'bi655066', 'bi 655066', '655066-01', '65506601', 'skyrizi'] for Skyrizi\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " 57 Trials found for Skyrizi\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Single Rising i.v. (Stage 1) and s.c. (Stage 2) Doses of BI 655066 in Male and Female Patients With Moderate to Severe Psoriasis (Randomised, Double-blind, Placebo-controlled Within Dose Groups)\n",
      "Phase 1 start date: 04/01/2012\n",
      "Interventions for study: BI 655066 (high i.v. dose); BI 655066 (high medium i.v. dose); BI 655066 (high s.c. dose); BI 655066 (low i.v. dose); BI 655066 (low medium i.v. dose); BI 655066 (low s.c. dose); BI 655066 (very high i.v. dose); BI 655066 (very low i.v. dose); Placebo, i.v.; Placebo, s.c.\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: A 48 Weeks, Phase II, Randomized, Double-blind, Placebo-controlled, Proof of Concept and Dose Finding Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Ankylosing Spondylitis.\n",
      "Phase 2 start date: 01/28/2014\n",
      "Interventions for study: placebo for risankizumab; risankizumab\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: BI 655066/ABBV-066 (Risankizumab) Versus Ustekinumab and Placebo Comparators in a Randomized Double Blind trIal for Maintenance Use in Moderate to Severe Plaque Type Psoriasis (UltIMMa-1)\n",
      "Phase 3 start date: 02/01/2016\n",
      "Interventions for study: placebo for risankizumab; placebo for ustekinumab; risankizumab; ustekinumab\n",
      "\n",
      "\n",
      "Querying ['pertuzumab', 'omnitarg', 'r1273', 'rg-1273', 'moab 2c4', 'r 1273', 'rg1273', 'r-1273', 'rg 1273', 'rhumab2c4', 'ro4368451', 'rhumab-2c4', 'ro-4368451', 'rhumab 2c4', 'phesgo', 'ro 4368451', 'perjeta'] for Perjeta\n",
      "\n",
      " 229 Trials found for Perjeta\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Phase I, Open-Label, Multicenter, Dose-Escalation Study of the Safety and Pharmacokinetics of a Recombinant Humanized Antibody to Her2 (rhuMAb 2C4) Administered Every 3 Weeks to Subjects With Advanced Solid Malignancies\n",
      "Phase 1 start date: 11/01/2001\n",
      "Interventions for study: rhuMAb 2C4\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: Open-Label, Phase II, Multicenter, Randomized Study of Efficacy and Safety for Two Different Doses of a Recombinant Humanized Antibody to HER2 (rhuMAb 2C4) Administered Every 3 Weeks to Patients With Metastatic Breast Cancer With Low Expression of HER2\n",
      "Phase 2 start date: 02/01/2003\n",
      "Interventions for study: Pertuzumab\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer\n",
      "Phase 3 start date: 02/12/2008\n",
      "Interventions for study: Docetaxel; Pertuzumab; Placebo; Trastuzumab\n",
      "\n",
      "\n",
      "Querying ['necitumumab', 'imc 11f8', 'imc-11f8', 'imc11f8', 'ly 3012211', 'ly3012211', 'ly-3012211', 'portraza', 'portrazza'] for Portrazza\n",
      "\n",
      " 23 Trials found for Portrazza\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: Phase I Study of the Fully Human Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody IMC-11F8 in Patients With Solid Tumors Who Have Failed Standard Therapy\n",
      "Phase 1 start date: 11/01/2004\n",
      "Interventions for study: IMC-11F8; IMC-11F8 I.V.\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: Open Label, Multicenter, Phase II Study Evaluating the Efficacy and Safety of IMC-11F8 in Combination With 5-FU/FA and Oxaliplatin (mFOLFOX-6) in Patients With Treatment-naïve, Locally-advanced or Metastatic Colorectal Cancer\n",
      "Phase 2 start date: 08/01/2007\n",
      "Interventions for study: 5-FU; Folinic acid (FA); IMC-11F8 (necitumumab); Oxaliplatin\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Randomized, Multicenter, Open-Label Phase 3 Study of Pemetrexed-Cisplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Pemetrexed-Cisplatin Chemotherapy Alone in the First-Line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer (NSCLC)\n",
      "Phase 3 start date: 11/02/2009\n",
      "Interventions for study: Cisplatin; Necitumumab; Pemetrexed\n",
      "\n",
      "\n",
      "Querying ['simeprevir', 'galexos', 'jnj-38733214-aaa', 'jnj38733214', 'r-494617', 'r494617', 'r 494617', 'tmc435', 'tmc 435', 'tmc-435', 'tmc-435350', 'tmc 435350', 'tmc435350', 'olysio'] for Olysio\n",
      "\n",
      " 91 Trials found for Olysio\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: Phase I, Double Blind, Randomized, Placebo-controlled Trial in Healthy Subjects to Examine the Safety, Tolerability and Pharmacokinetics of Increasing Oral Doses of TMC435350 After Single and Repeated Dosing, Followed by an Open Label Repeated Dosing Session in 6 HCV genotype1 Infected Patients.\n",
      "Phase 1 start date: 01/01/2007\n",
      "Interventions for study: TMC435350; Placebo\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: A Blinded, Randomized, Placebo-controlled Trial in Genotype 1 Hepatitis C-Infected Subjects to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Repeated Doses of TMC435350, With or Without Peginterferon Alpha-2a and Ribavirin\n",
      "Phase 2 start date: 01/01/2008\n",
      "Interventions for study: Peginterferon (PegIFNα-2a); Placebo; Ribavirin; TMC435\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Phase III, Open-label Trial in Japan to Investigate the Efficacy and Safety of TMC435 as Part of a Treatment Regimen Including Peginterferon Alfa-2a and Ribavirin in Genotype 1, Hepatitis C-infected Subjects Who Relapsed After Previous IFN-based Therapy\n",
      "Phase 3 start date: 01/01/2011\n",
      "Interventions for study: Pegylated interferon (pegIFN alpha-2a); Ribavirin (RBV); TMC435\n",
      "\n",
      "\n",
      "Querying ['abiraterone', 'cb 7598', 'cb-7598', 'cb7598', 'zaitiga', 'zaytiga', 'zitiga', '212082', 'cb-7630', 'cb7630', 'cb 7630', 'aviraterone', 'zytiga'] for Zytiga\n",
      "\n",
      " 263 Trials found for Zytiga\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: An Expanded Access Open Label Study of CB7630 (Abiraterone Acetate) in Patients With Advanced Prostate Cancer Who Have Completed CB7630 Clinical Study COU-AA-001\n",
      "Phase 1 start date: 04/01/2007\n",
      "Interventions for study: Abiraterone acetate; Glucocorticoid\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: A Phase II Open Label Study of CB7630 (Abiraterone Acetate) in Patients With Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy\n",
      "Phase 2 start date: 11/01/2006\n",
      "Interventions for study: Abiraterone acetate; Glucocorticoid\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy\n",
      "Phase 3 start date: 05/01/2008\n",
      "Interventions for study: Abiraterone acetate; Placebo; Prednisone/prednisolone\n",
      "\n",
      "\n",
      "Querying ['idelalisib', 'cal 101', 'cal-101', 'cal101', 'gs 1101', 'gs-1101', 'gs1101', 'idela', 'zydelig'] for Zydelig\n",
      "\n",
      " 61 Trials found for Zydelig\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Phase 1 Sequential Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of CAL-101 in Patients With Select, Relapsed or Refractory Hematologic Malignancies\n",
      "Phase 1 start date: 06/01/2008\n",
      "Interventions for study: CAL-101\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: A Phase 2 Single Arm Study to Investigate the Safety and Clinical Activity of Idelalisib Alone and in Combination With Rituximab in Elderly Subjects With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma\n",
      "Phase 2 start date: 10/01/2010\n",
      "Interventions for study: Idelalisib; Rituximab\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia\n",
      "Phase 3 start date: 04/01/2012\n",
      "Interventions for study: Idelalisib; Placebo to match idelalisib; Rituximab\n",
      "\n",
      "\n",
      "Querying ['iloprost', 'endoprost', 'ilocit', 'iloderm', 'ilomedin', 'sh-401', 'sh401', 'sh 401', 'vectura', 'zk-36375', 'zk36375', 'zk 36375', 'breelib', 'ciloprost', 'e-1030', 'e1030', 'e 1030', 'bayq 6256', 'bayq6256', 'bayq-6256', 'ventavis'] for Ventavis\n",
      "\n",
      " 139 Trials found for Ventavis\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: Effects of Iloprost on Hypoxic Pulmonary Vasoconstriction and Exercise Capacity at High Altitude\n",
      "Phase 1 start date: 07/01/2008\n",
      "Interventions for study: iloprost\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: Comparision Between Maximally Tolerated Intravenous Iloprost Doses Versus Low-Dosed Iloprost for a 21-Day Treatment Course\n",
      "Phase 2 start date: 09/01/1997\n",
      "Interventions for study: iloprost; iloprost low dose; iloprost therapy up to 2 ng/kg x min\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: no data\n",
      "Phase 3 start date: 12/01/1995\n",
      "Interventions for study: iloprost\n",
      "\n",
      "\n",
      "Querying ['dacomitinib', 'pf-00299804', 'pf00299804', 'pf 00299804', 'pf-299', 'pf299', 'pf 299', 'pf-804', 'pf804', 'pf 804', 'vizimpro'] for Vizimpro\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " 57 Trials found for Vizimpro\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A PHASE 1, OPEN-LABEL, DOSE-ESCALATION STUDY TO EVALUATE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF 2 DOSING SCHEDULES OF PF-00299804 IN PATIENTS WITH ADVANCED MALIGNANT SOLID TUMORS\n",
      "Phase 1 start date: 10/11/2005\n",
      "Interventions for study: PF-00299804\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: A PHASE 1/2, OPEN-LABEL, SINGLE ARM TRIAL TO DETERMINE THE RECOMMENDED PHASE 2 DOSE AND EVALUATE THE EFFICACY OF PF-00299804 IN PATIENTS IN KOREA WITH KRAS WILD TYPE ADVANCED NSCLC, WHICH IS REFRACTORY TO CHEMOTHERAPY AND ERLOTINIB OR GEFITINIB\n",
      "Phase 2 start date: 02/05/2008\n",
      "Interventions for study: PF-00299804\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Double Blind Placebo Controlled Randomized Trial of PF-804 in Patients With Incurable Stage IIIB/IV Non-Small Cell Lung Cancer After Failure of Standard Therapy for Advanced or Metastatic Disease\n",
      "Phase 3 start date: 09/04/2009\n",
      "Interventions for study: PF-00299804; Placebo\n",
      "\n",
      "\n",
      "Querying ['letermovir', 'aic 246', 'aic-246', 'aic246', 'mk-8228', 'mk8228', 'mk 8228', 'aic-001', 'aic-090027', 'bay-73-6327', 'aic001', 'aic090027', 'bay736327', 'aic 001', 'aic 090027', 'bay 736327', 'prevymis'] for Prevymis\n",
      "\n",
      " 18 Trials found for Prevymis\n",
      "\n",
      " No Phase 1 Data found for Prevymis\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Safety, Tolerability and Antiviral Activity of 12 Weeks' Treatment With a New Antiviral HCMV Drug\n",
      "Phase 2 start date: 03/01/2010\n",
      "Interventions for study: 120 mg AIC246; 240 mg AIC246; 60 mg AIC246; Placebo\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Phase III Randomized, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-8228 (Letermovir) for the Prevention of Clinically Significant Human Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients\n",
      "Phase 3 start date: 06/06/2014\n",
      "Interventions for study: Letermovir; Placebo\n",
      "\n",
      "\n",
      "Querying ['semaglutide', 'wegovy', 'nn-9535', 'nn9535', 'nnc 0113-0217', 'nnc-0113-0217', 'nn 9535', 'nnc0113-0217', 'ozempic'] for Ozempic\n",
      "\n",
      " 256 Trials found for Ozempic\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Randomised, Double-blind, Placebo-controlled, Dose Escalation Trial of Single Subcutaneous Doses of NNC 0113-0217 to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male Subjects\n",
      "Phase 1 start date: 06/11/2007\n",
      "Interventions for study: Placebo; semaglutide\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: Investigation of Safety and Efficacy of Five Doses of Semaglutide Versus Placebo and Open-label Liraglutide, as Add on Therapy, in Subjects Diagnosed With Type 2 Diabetes Currently Treated With Metformin or Controlled With Diet and Exercise A 12 Week Multi-centre, Multi National, Double-blind, Placebo-controlled, Randomised, Nine Armed Parallel Group, Dose Finding Trial\n",
      "Phase 2 start date: 06/03/2008\n",
      "Interventions for study: liraglutide; placebo; semaglutide\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes (SUSTAIN™ 6 - Long-term Outcomes)\n",
      "Phase 3 start date: 02/21/2013\n",
      "Interventions for study: placebo; semaglutide\n",
      "\n",
      "\n",
      "Querying ['tapentadol', 'nucynta', 'bn200', 'bn 200', 'bn-200', 'cg-5503', 'cg5503', 'cg 5503', 'r331333', 'jns024', 'palexia', 'yantil', 'tapenta'] for Tapenta\n",
      "\n",
      " 68 Trials found for Tapenta\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: Investigation of the Effect on the QT/QTc Interval After Multiple Dose Oral Administration (100 and 200 mg Bid) of CG5503 PR in a Randomised, Double-blind, Double-dummy Placebo- and Moxifloxacin-controlled 4- Way Cross-over Phase I Study in 48 Healthy Male and Female Volunteers\n",
      "Phase 1 start date: 03/01/2003\n",
      "Interventions for study: 100 mg CG5503 (tapentadol hydrochloride) PR tablet; 400 mg Moxifloxacin tablet (overencapsulated); Placebo matching CG5503 PR tablet; Placebo matching moxifloxacin capsule\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: 4-Week Randomized Multicenter DB, Placebo- and Active-controlled, Parallel-group, Forced-titration Phase 2B Study of Efficacy and Safety With CG5503 Prolonged Release (PR) to 233 mg BID and Oxycodone PR to 20 mg BID vs Placebo in Subjects With Moderate to Severe Chronic Pain of Knee Osteoarthritis\n",
      "Phase 2 start date: 07/01/2004\n",
      "Interventions for study: tapentadol HCl\n",
      "\n",
      " No Phase 3 Data found for Tapenta\n",
      "\n",
      "\n",
      "Querying ['midostaurin', 'benzoylstaurosporine', 'cgp-41251', 'cgp 41251', 'cgp41251', 'pkc-412', 'pkc412', 'pkc 412', 'rydapt'] for Rydapt\n",
      "\n",
      " 46 Trials found for Rydapt\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Phase IB, Open-Label Study to Determine the Safety and Pharmacokinetics of Twice Daily Oral Dosing of PKC412 Administered in Combinations Sequentially and Concomitantly With Daunorubicin and Cytarabine for Standard Induction Therapy, and High Dose Cytarabine for Consolidation in Patients With Acute Myeloid Leukemia (AML)\n",
      "Phase 1 start date: 02/01/2004\n",
      "Interventions for study: cytarabine; daunorubicin hydrochloride; midostaurin\n",
      "\n",
      " No Phase 2 Data found for Rydapt\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) (IND #101261) or Placebo in Newly Diagnosed Patients < 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia (AML)\n",
      "Phase 3 start date: 04/01/2008\n",
      "Interventions for study: cytarabine; daunorubicin; dexamethasone acetate; midostaurin; placebo\n",
      "\n",
      "\n",
      "Querying ['sacituzumab govitecan', 'hrs 7sn38', 'hrs7-sn38', 'immu 132', 'immu-132', 'hrs7sn38', 'immu132', 'gs-0132', 'gs0132', 'gs 0132', 'trodelvy'] for Trodelvy\n",
      "\n",
      " 51 Trials found for Trodelvy\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Phase 1, Open-Label, Dose-Escalation Study to Determine an Appropriate Starting Dose of Sacituzumab Govitecan in Subjects With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment\n",
      "Phase 1 start date: 04/06/2021\n",
      "Interventions for study: Sacituzumab Govitecan-hziy\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: Randomized Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Relapsed/Refractory Triple-Negative Breast Cancer\n",
      "Phase 2 start date: 08/01/2016\n",
      "Interventions for study: IMMU-132 infusion is administered to participants in one arm for the study; IMMU-132 plus Carboplatin infusion\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan Versus Treatment of Physician Choice in Patients With Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments\n",
      "Phase 3 start date: 11/07/2017\n",
      "Interventions for study: Capecitabine; Eribulin; Gemcitabine; Sacituzumab govitecan; Vinorelbine\n",
      "\n",
      "\n",
      "Querying ['atezolizumab', 'mpdl 3280a', 'mpdl-3280a', 'mpdl3280a', 'rg-7446', 'rg7446', 'rg 7446', 'mpdl-3280a', 'ro-5541267', 'mpdl3280a', 'ro5541267', 'mpdl 3280a', 'ro 5541267', 'tecentriq'] for Tecentriq\n",
      "\n",
      " 594 Trials found for Tecentriq\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Atezolizumab (MPDL3280A) Administered Intravenously as a Single Agent to Patients With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies\n",
      "Phase 1 start date: 06/21/2011\n",
      "Interventions for study: Atezolizumab\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: An Open-Label, Multicenter Extension Study of Trastuzumab Emtansine Administered as a Single Agent or in Combination With Other Anti-Cancer Therapies in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd-Sponsored Trastuzumab Emtansine Study\n",
      "Phase 2 start date: 10/16/2008\n",
      "Interventions for study: Atezolizumab; Docetaxel; Paclitaxel; Pertuzumab; Trastuzumab; Trastuzumab Emtansine\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer After Failure With Platinum Containing Chemotherapy\n",
      "Phase 3 start date: 03/11/2014\n",
      "Interventions for study: Atezolizumab; Docetaxel\n",
      "\n",
      "\n",
      "Querying ['regorafenib', 'bay 73-4506', 'bay-73-4506', 'bay-734506', 'bay 734506', 'bay734506', 'resihance', 'fluoro-sorafenib', 'stivarga'] for Stivarga\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " 216 Trials found for Stivarga\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: Open Label, Phase I Study to Determine the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetics, and Biomarker Status of BAY73-4506 in Patients With Advanced Malignancies\n",
      "Phase 1 start date: 02/01/2007\n",
      "Interventions for study: Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg; Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg; Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg; Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg; Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg; HCC Child-Pugh A expansion cohort: Regorafenib 100 mg; HCC Child-Pugh B expansion cohort: Regorafenib 100 mg; NSCLC expansion cohort: Regorafenib 100 mg\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: A Phase II Uncontrolled Study of BAY73-4506 in Previously Untreated Patients With Metastatic or Unresectable Renal Cell Cancer (RCC)\n",
      "Phase 2 start date: 04/30/2008\n",
      "Interventions for study: Regorafenib (Stivarga, BAY73-4506)\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus BSC Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy\n",
      "Phase 3 start date: 04/01/2010\n",
      "Interventions for study: Best Supportive Care (BSC); Placebo; Regorafenib (Stivarga, BAY73-4506)\n",
      "\n",
      "\n",
      "Querying ['vemurafenib', '5185426', '51-85426', 'plx4032', 'rg7204', 'plx-4032', 'rg-7204', 'plx 4032', 'rg 7204', 'r7204', 'r 7204', 'r-7204', 'zelboraf'] for Zelboraf\n",
      "\n",
      " 141 Trials found for Zelboraf\n",
      "\n",
      " No Phase 1 Data found for Zelboraf\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: An Open-label Multicenter Study on the Efficacy of Continuous Oral Dosing of Vemurafenib on Tumour Response in Previously Treated Patients With Metastatic Melanoma\n",
      "Phase 2 start date: 09/30/2009\n",
      "Interventions for study: vemurafenib\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: BRIM 3: A Randomized, Open-Label, Controlled, Multicenter, Phase III Study in Previously Untreated Patients With Unresectable Stage IIIC or Stage IV Melanoma With V600E BRAF Mutation Receiving Vemurafenib (RO5185426) or Dacarbazine\n",
      "Phase 3 start date: 01/01/2010\n",
      "Interventions for study: Dacarbazine; Vemurafenib\n",
      "\n",
      "\n",
      "Querying ['asenapine', 'org5222', 'org 5222', 'org-5222', 'secuado', 'sycrest', 'atisenap', 'me-2136', 'sch-900274', 'me2136', 'sch900274', 'me 2136', 'sch 900274', 'saphris'] for Saphris\n",
      "\n",
      " 49 Trials found for Saphris\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Sequential Groups, Open Label, Rising Multiple Dose Study to Assess the Pharmacokinetics, Safety and Tolerability of Sublingual Asenapine in a Pediatric Population With Schizophrenia or Bipolar I Disorder\n",
      "Phase 1 start date: 07/18/2010\n",
      "Interventions for study: Asenapine 10 mg; Asenapine 2.5 mg; Asenapine 5 mg\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: A Single-center, Open-label, 2-way Crossover Relative Bioavailability and Safety Trial With Two Differing Strength Tablets (3 x 5 mg vs. 1 x 15 mg) of Sublingually Administered Org 5222 in Subjects With Schizophrenia or Schizoaffective Disorder.\n",
      "Phase 2 start date: 10/01/2002\n",
      "Interventions for study: Asenapine 1x15mg followed by 3x5mg; Asenapine 3x5mg followed by 1x15mg\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Phase III, Double-Blind, Randomized, Active-Controlled, Two-Armed, Multicenter, Efficacy and Safety Assessment (ACTAMESA) of Org 5222 and Olanzapine in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder\n",
      "Phase 3 start date: 09/04/2003\n",
      "Interventions for study: asenapine; olanzapine\n",
      "\n",
      "\n",
      "Querying ['finafloxacin', 'by377', 'al-60371', 'by 377', 'by-377', 'al60371', 'al 60371', 'exe 844', 'exe-844', 'exe844', 'gastrochinolon', 'gastroquinolone', 'xtoro'] for Xtoro\n",
      "\n",
      " 14 Trials found for Xtoro\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Double-Blind, Placebo-Controlled, Randomized, Dose-Escalating Study of Single and Multiple Oral Doses of Finafloxacin Hydrochloride in Healthy Subjects and a Study of H. Pylori Treatment in Healthy Carriers\n",
      "Phase 1 start date: 08/01/2007\n",
      "Interventions for study: Finafloxacin hydrochloride\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: An Open-Label, Randomized, Multicenter, Two-Arms Efficacy and Safety Study of 14 Days Treatment With Finafloxacin 400 mg b.i.d. Plus Amoxicillin 1000 mg b.i.d.Versus Finafloxacin 400 mg b.i.d. Plus Esomeprazole 40 mg b.i.d. in Patients With Helicobacter Pylori Infection\n",
      "Phase 2 start date: 09/01/2008\n",
      "Interventions for study: Finafloxacin + Amoxicillin; Finafloxacin + Esomeprazole\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: Safety and Efficacy Evaluation of Topical AL-60371 Otic Suspension, 0.3% in the Treatment of Acute Otitis Externa\n",
      "Phase 3 start date: 03/01/2012\n",
      "Interventions for study: AL-60371 Vehicle; AL-60371, 0.3% Otic Suspension\n",
      "\n",
      "\n",
      "Querying ['cilastatin/relebactam/imipenem', 'imi/rel', 'imipenem/cilastatin/relebactam', 'imipenem/relebactam/cilastatin', 'cilastatin/imipenem/relebactam', 'relebactam/cilastatin/imipenem', 'relebactam/imipenem/cilastatin', 'mk-7655a', 'mk7655a', 'mk 7655a', 'recarbrio'] for Recarbrio\n",
      "\n",
      " 6 Trials found for Recarbrio\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Phase 1b, Open-label, Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of MK-7655A in Pediatric Subjects From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative Infections\n",
      "Phase 1 start date: 11/06/2017\n",
      "Interventions for study: IMI/REL FDC\n",
      "\n",
      " No Phase 2 Data found for Recarbrio\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Multi-national Phase 3, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Subjects With Hospital-Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia\n",
      "Phase 3 start date: 09/18/2018\n",
      "Interventions for study: IMI/REL FDC; Linezolid; PIP/TAZ FDC\n",
      "\n",
      "\n",
      "Querying ['guselkumab', 'cnto1959', 'cnto-1959', 'cnto 1959', 'tremfya'] for Tremfya\n",
      "\n",
      " 68 Trials found for Tremfya\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Randomized, Double-blind, Placebo-controlled, Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CNTO 1959 Following a Single Intravenous or a Single Subcutaneous Administration in Healthy Subjects and in Subjects With Moderate to Severe Psoriasis\n",
      "Phase 1 start date: 06/04/2009\n",
      "Interventions for study: CNTO 1959; Placebo\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: A Phase 2 Multicenter, Randomized, Placebo- and Active-Comparator-Controlled, Dose-Ranging Trial to Evaluate CNTO 1959 for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis (X-PLORE)\n",
      "Phase 2 start date: 11/10/2011\n",
      "Interventions for study: Adalimumab; CNTO 1959 (100 mg); CNTO 1959 (15 mg); CNTO 1959 (200 mg); CNTO 1959 (5 mg); CNTO 1959 (50 mg); Placebo\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Guselkumab for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab\n",
      "Phase 3 start date: 10/07/2014\n",
      "Interventions for study: Guselkumab; Placebo for guselkumab; Placebo for ustekinumab; Ustekinumab\n",
      "\n",
      "\n",
      "Querying ['tudorza', 'las-34273', 'las34273', 'las 34273', 'aclidinium', 'krp-ab1102', 'krpab1102', 'krp ab1102', 'las-34273', 'las34273', 'las 34273', 'tudorza pressair'] for Tudorza Pressair\n",
      "\n",
      " 41 Trials found for Tudorza Pressair\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Phase I, Open-Label, Single and Multiple Dose (Twice-Daily), Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide 400 μg Administered by Inhalation in Healthy Chinese Participants\n",
      "Phase 1 start date: 10/14/2021\n",
      "Interventions for study: Aclidinium Bromide 400 μg\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: A Randomised, 4-week, Placebo-controlled, Double-blind, 6 Arm Parallel Group, Dose-finding Clinical Trial, to Assess the Efficacy, Safety and Pharmacokinetics of Three Different Doses of Formoterol Combined With the Inhaled Anticholinergic Aclidinium Bromide, Aclidinium Bromide Monotherapy and Formoterol Monotherapy All Administrated Once Daily by Inhalation Via Almirall Inhaler in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease.\n",
      "Phase 2 start date: 02/01/2008\n",
      "Interventions for study: Aclidinium bromide and formoterol; Aclidinium bromide and formoterol placebo\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: Clinical Trial Assessing Efficacy and Safety of LAS34273 in Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD) Patients\n",
      "Phase 3 start date: 07/01/2006\n",
      "Interventions for study: Aclidinium bromide; Placebo\n",
      "\n",
      "\n",
      "Querying ['ertugliflozin', 'mk-8835', 'mk8835', 'mk 8835', 'pf-04971729', 'pf04971729', 'pf 04971729', 'pf-4971729', 'pf4971729', 'pf 4971729', 'segluromet', 'steglujan', 'steglatro'] for Steglatro\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " 33 Trials found for Steglatro\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Phase 1 Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of PF-04971729 After Administration of Single Escalating Oral Doses Under Fed and Fasted Conditions in Healthy Volunteers\n",
      "Phase 1 start date: 10/16/2009\n",
      "Interventions for study: Ertugliflozin; Placebo to Ertugliflozin\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: A 12-Week, Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging, Parallel Group Study to Evaluate the Safety, Tolerability and Efficacy Of Once Daily PF-04971729 And Sitagliptin On Glycemic Control And Body Weight In Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin\n",
      "Phase 2 start date: 02/24/2010\n",
      "Interventions for study: Ertugliflozin 1 mg; Ertugliflozin 25 mg; Ertugliflozin 5 mg; Metformin; Placebo to Ertugliflozin; Placebo to Sitagliptin; Sitagliptin 100 mg\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Phase 3, Randomized, Double-blind, Placebo-controlled, 26-week Multicenter Study With a 26-Week Extension to Evaluate the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise\n",
      "Phase 3 start date: 10/09/2013\n",
      "Interventions for study: Ertugliflozin 10 mg; Ertugliflozin 5 mg; Glimepiride; Metformin; Placebo to Ertugliflozin; Placebo to Metformin\n",
      "\n",
      "\n",
      "Querying ['talazoparib', 'bmn673', 'bmn 673', 'bmn-673', 'lt-673', 'lt673', 'lt 673', 'mdv-380', 'mdv 380', 'mdv380', 'lt-006673', 'lt-00673', 'lt006673', 'lt00673', 'lt 006673', 'lt 00673', 'talzenna'] for Talzenna\n",
      "\n",
      " 103 Trials found for Talzenna\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Phase 1, First In Human, Single-arm, Open-label Study Of Once A Day, Orally Administered Talazoparib (Bmn 673) In Patients With Advanced Or Recurrent Solid Tumors\n",
      "Phase 1 start date: 01/03/2011\n",
      "Interventions for study: Talazoparib\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)\n",
      "Phase 2 start date: 03/01/2010\n",
      "Interventions for study: ABT-888; AMG 386 and Trastuzumab; AMG 386 with or without Trastuzumab; AMG 479 (Ganitumab) plus Metformin; ARX788; ARX788 + Cemiplimab; Amcenestrant; Amcenestrant + Abemaciclib; Amcenestrant + Letrozole; Cemiplimab; Cemiplimab plus REGN3767; Datopotamab deruxtecan; Datopotamab deruxtecan + Durvalumab; Durvalumab plus Olaparib; Ganetespib; MK-2206 with or without Trastuzumab; Neratinib; Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab; Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab; PLX3397; Patritumab and Trastuzumab; Pembrolizumab - 4 cycle; Pembrolizumab - 8 cycle; Pertuzumab and Trastuzumab; SD-101 + Pembrolizumab; SGN-LIV1A; SYD985 ([vic-]trastuzumab duocarmazine); Standard Therapy; T-DM1 and Pertuzumab; Talazoparib plus Irinotecan; Trilaciclib with or without trastuzumab + pertuzumab; Tucatinib plus trastuzumab and pertuzumab; VV1 + Cemiplimab\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A PHASE 3, OPEN-LABEL, RANDOMIZED PARALLEL,2-ARM,MULTI-CENTER STUDY OF TALAZOPARIB(BMN 673) VERSUS PHYSICIAN'S CHOICE IN GERMLINE BRCA MUTATION SUBJECTS WITH LOCALLY ADVANCED AND/OR METASTATIC BREAST CANCER, WHO HAVE RECEIVED PRIOR CHEMOTHERAPY REGIMENS FOR METASTATIC DISEASE\n",
      "Phase 3 start date: 10/14/2013\n",
      "Interventions for study: Physician's-Choice; talazoparib\n",
      "\n",
      "\n",
      "Querying ['ponesimod', 'act 128800', 'act-128800', 'act128800', 'rg 3477', 'r 3477', 'rg-3477', 'r-3477', 'rg3477', 'r3477', 'ponvory'] for Ponvory\n",
      "\n",
      " 15 Trials found for Ponvory\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: Single-center, Open-label, Parallel-group Study to Evaluate the Pharmacokinetics, Tolerability, and Safety of a Single Dose of 40 mg ACT-128800 in Japanese and Caucasian Healthy Male and Female Subjects\n",
      "Phase 1 start date: 02/01/2009\n",
      "Interventions for study: ACT-128800\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: Multicenter, Randomized, Double-blind, Placebo-controlled, Phase IIa Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800, an S1P1 Receptor Agonist, Administered for 6 Weeks to Subjects With Moderate to Severe Chronic Plaque Psoriasis\n",
      "Phase 2 start date: 10/01/2008\n",
      "Interventions for study: ACT-128800; Placebo\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: Multicenter, Randomized, Double-blind, Parallel-group, Active-controlled, Superiority Study to Compare the Efficacy and Safety of Ponesimod to Teriflunomide in Subjects With Relapsing Multiple Sclerosis\n",
      "Phase 3 start date: 06/04/2015\n",
      "Interventions for study: ponesimod; teriflunomide\n",
      "\n",
      "\n",
      "Querying ['oxcarbazepine', 'tri 476', 'tri-476', 'tri476', 'gp 47680', 'gp-47680', 'gp47680', 'kin493', 'kin-493', 'kin 493', 'spn804', 'spn-804', 'spn 804', 'npc 04', 'npc04', 'npc-04', 'trileptal'] for Trileptal\n",
      "\n",
      " 48 Trials found for Trileptal\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: Tolerability and Pharmacokinetics of a Single 900 mg Oral Dose of BIA 2-093 and Oxcarbazepine in Healthy Volunteers\n",
      "Phase 1 start date: 03/01/2002\n",
      "Interventions for study: BIA 2-093; Oxcarbazepine\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: OxCarbazepine as a Neuroprotective Agent in MS: A Phase 2a Trial\n",
      "Phase 2 start date: 10/01/2014\n",
      "Interventions for study: Oxcarbazepine; Placebo\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Multicenter, Rater-blind, Randomized, Age-stratified, Parallel-group Study Comparing Two Doses of Oxcarbazepine as Adjunctive Therapy in Pediatric Patients With Inadequately-controlled Partial Seizures.\n",
      "Phase 3 start date: 06/01/2002\n",
      "Interventions for study: oxcarbazepine\n",
      "\n",
      "\n",
      "Querying ['polatuzumab', 'dcds4501a', 'dcds-4501a', 'dcds 4501a', 'fcu-2711', 'fcu2711', 'fcu 2711', 'rg-7596', 'rg7596', 'rg 7596', 'ro-5541077', 'ro5541077', 'ro 5541077', 'polivy'] for Polivy\n",
      "\n",
      " 41 Trials found for Polivy\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: An Open-Label, Multicenter, Phase I Trial of the Safety and Pharmacokinetics Of Escalating Doses of DCDS4501A in Patients With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and DCDS4501A in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma\n",
      "Phase 1 start date: 03/22/2011\n",
      "Interventions for study: Polatuzumab Vedotin; Rituximab\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: Efficacy and Safety of Topic Ketorolac to Treat Center Point Thickness Secondary to Panphotocoagulation in Proliferative Diabetic Retinopathy\n",
      "Phase 2 start date: 06/01/2009\n",
      "Interventions for study: Ketorolac tromethamine; Polivynilic alcohol\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Polatuzumab Vedotin in Combination With Rituximab and CHP (R-CHP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients With Diffuse Large B-Cell Lymphoma\n",
      "Phase 3 start date: 11/16/2017\n",
      "Interventions for study: Cyclophosphamide; Doxorubicin; Polatuzumab Vedotin; Polatuzumab vedotin Placebo; Prednisone; Rituximab; Vincristine; Vincristine Placebo\n",
      "\n",
      "\n",
      "Querying ['r-76477', 'ro-76477', 'ro76477', 'r76477', 'r 76477', 'ro 76477', 'invega', 'paliperidone', 'byannli', 'sustenna', 'trevicta', 'ro-92670', 'ro92670', 'ro 92670', 'xeplion'] for Xeplion\n",
      "\n",
      " 164 Trials found for Xeplion\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Phase 1 Study to Compare the Tolerability of OROS Paliperidone (Extended Release) With Immediate-release (IR) Risperidone in Subjects With Schizophrenia\n",
      "Phase 1 start date: 03/01/2003\n",
      "Interventions for study: extended-release (ER) OROS paliperidone\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: A Double-blind, Placebo-controlled, Randomized Study Evaluating the Effect of Paliperidone ER Compared With Placebo on Sleep Architecture in Subjects With Schizophrenia\n",
      "Phase 2 start date: 02/01/2005\n",
      "Interventions for study: paliperidone ER\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: Pharmacokinetics, Tolerability, and Safety of Paliperidone After Repeated Intramuscular Injection of Paliperidone Palmitate in the Arm or the Buttock of Subjects With Schizophrenia\n",
      "Phase 3 start date: 08/01/2003\n",
      "Interventions for study: Paliperidone Palmitate\n",
      "\n",
      "\n",
      "Querying ['nivolumab', 'bms936558', 'bms 936558', 'bms-936558', 'gtpl7335', 'mdx 1106', 'mdx-1106', 'ono 4538', 'ono-4538', 'ono4538', 'mdx1106', 'opdivo'] for Opdivo\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " 1357 Trials found for Opdivo\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Phase 1, Open Label, Dose-escalation, Safety and Pharmacokinetic Study of MDX-1106 in Patients With Selected or Relapsed Malignancies\n",
      "Phase 1 start date: 08/01/2006\n",
      "Interventions for study: MDX-1106\n",
      "\n",
      " No Phase 2 Data found for Opdivo\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Randomized, Open-Label, Phase 3 Study of Nivolumab (BMS-936558) vs. Everolimus in Subjects With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy\n",
      "Phase 3 start date: 10/09/2012\n",
      "Interventions for study: Everolimus; Nivolumab\n",
      "\n",
      "\n",
      "Querying ['gilteritinib', 'asp-2215', 'asp2215', 'asp 2215', 'xospata'] for Xospata\n",
      "\n",
      " 40 Trials found for Xospata\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Phase 1 Open-label, Dose-escalation Study Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP2215 in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia\n",
      "Phase 1 start date: 06/16/2014\n",
      "Interventions for study: Gilteritinib\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: Phase II Study of Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With AML, HR MDS, or Myeloid Blast Phase of CML\n",
      "Phase 2 start date: 05/19/2014\n",
      "Interventions for study: Cladribine; Cytarabine; Gilteritinib; Idarubicin; Laboratory Biomarker Analysis; Midostaurin; Venetoclax\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation\n",
      "Phase 3 start date: 10/20/2015\n",
      "Interventions for study: Azacitidine; FLAG-IDA (Granulocyte-Colony Stimulating Factor (G-CSF), Fludarabine, Cytarabine, Idarubicin); LoDAC (Low Dose Cytarabine); MEC (Mitoxantrone, Etoposide, Cytarabine); gilteritinib\n",
      "\n",
      "\n",
      "Querying ['delstrigo', 'doravirine', 'mk 1439', 'mk-1439', 'mk1439', 'pifeltro'] for Pifeltro\n",
      "\n",
      " 39 Trials found for Pifeltro\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiretroviral Activity of MK-1439 in HIV-1 Infected Patients\n",
      "Phase 1 start date: 10/21/2011\n",
      "Interventions for study: Doravirine; Placebo\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients\n",
      "Phase 2 start date: 10/12/2012\n",
      "Interventions for study: Doravirine; Efavirenz; Placebo for Doravirine; Placebo for Efavirenz; TRUVADA®\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Phase 3 Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Doravirine (MK-1439) 100 mg Once Daily Versus Darunavir 800 mg Once Daily Plus Ritonavir 100 mg Once Daily, Each in Combination With TRUVADA™ or EPZICOM™/KIVEXA™, in Treatment-Naïve HIV-1 Infected Subjects\n",
      "Phase 3 start date: 12/01/2014\n",
      "Interventions for study: Darunavir; Doravirine; Ritonavir; TRUVADA™ or EPZICOM™/KIVEXA™\n",
      "\n",
      "\n",
      "Querying ['capmatinib', 'inc-280', 'inc280', 'incb 28060', 'incb-28060', 'inc 280', 'incb28060', 'incb 028060', 'incb-028060', 'incb028060', 'tabrecta'] for Tabrecta\n",
      "\n",
      " 48 Trials found for Tabrecta\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Phase 1, Open-label, Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of INCB028060 in Subjects With Advanced Malignancies\n",
      "Phase 1 start date: 01/01/2010\n",
      "Interventions for study: INCB028060\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: A Phase IB/II, Open Label, Multicenter Study of INC280 Administered Orally in Combination With Gefitinib in Adult Patients With EGFR Mutated, c-MET-amplified Non-small Cell Lung Cancer Who Have Progressed After EGFR Inhibitor Treatment\n",
      "Phase 2 start date: 04/05/2012\n",
      "Interventions for study: Gefitinib; INC280\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: Molecular Profiling of Advanced Soft-tissue Sarcomas. A Phase III Study\n",
      "Phase 3 start date: 10/19/2019\n",
      "Interventions for study: Capmatinib; Ceritinib; Glasdegib; Lapatinib; Next Generation sequencing exome; Nilotinib; Olaparib and Durvalumab; Palbociclib; TAS-120; Trametinib; Trametinib and Dabrafenib\n",
      "\n",
      "\n",
      "Querying ['fostemsavir', 'bms 663068', 'bms-663068', 'bms663068', 'bms 626529', 'bms626529', 'bms-626529', 'gsk 3684934', 'gsk-3684934', 'gsk3684934', 'temsavir prodrug', 'rukobia'] for Rukobia\n",
      "\n",
      " 21 Trials found for Rukobia\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: Open-Label, Single-Sequence Study to Evaluate the Pharmacokinetic Interaction of BMS-663068 With Darunavir/Ritonavir and/or Etravirine in Healthy Subjects\n",
      "Phase 1 start date: 02/01/2014\n",
      "Interventions for study: BMS-663068; Darunavir (DRV); Etravirine (ETR); Ritonavir (RTV)\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: Randomized, Open Label, Multiple-Dose Study to Evaluate the Pharmacodynamics, Safety and Pharmacokinetics of BMS-663068 in HIV-1 Infected Subjects\n",
      "Phase 2 start date: 11/23/2009\n",
      "Interventions for study: BMS-663068; Ritonavir\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)\n",
      "Phase 3 start date: 02/23/2015\n",
      "Interventions for study: BMS-663068; Placebo\n",
      "\n",
      "\n",
      "Querying ['fx 006', 'fx-006', 'fx 1006', 'fx-1006', 'fx006', 'fx1006', 'vyndamax', 'tafamidis', '6291826', 'vyndaqel'] for Vyndaqel\n",
      "\n",
      " 49 Trials found for Vyndaqel\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: Pharmacokinetics Of Orally Administered Fx-1006A In Subjects With Hepatic Dysfunction\n",
      "Phase 1 start date: 11/01/2010\n",
      "Interventions for study: Fx-1006A\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients With Non-V30M Transthyretin Amyloidosis\n",
      "Phase 2 start date: 06/01/2008\n",
      "Interventions for study: Fx-1006A\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: OPEN-LABEL SAFETY AND EFFICACY EVALUATION OF FX-1006A IN SUBJECTS WITH TRANSTHYRETIN (TTR) AMYLOIDOSIS\n",
      "Phase 3 start date: 08/05/2009\n",
      "Interventions for study: Tafamidis\n",
      "\n",
      "\n",
      "Querying ['enzalutamide', 'mdv 3100', 'mdv-3100', 'mdv3100', 'asp-9785', 'asp9785', 'asp 9785', 'xtandi'] for Xtandi\n",
      "\n",
      " 255 Trials found for Xtandi\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A PHASE 1, OPEN-LABEL, DOSE-ESCALATION SAFETY AND PHARMACOKINETIC STUDY OF MDV3100 IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER\n",
      "Phase 1 start date: 07/23/2007\n",
      "Interventions for study: MDV3100\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: A Study Of Continuous Oral Dosing Of A Novel Antiandrogen Mdv3100, In Castration-resistant Bone Metastatic Prostate Cancer Patients Evaluating The Tumor Micro-enviroment\n",
      "Phase 2 start date: 02/18/2010\n",
      "Interventions for study: Enzalutamide\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: Affirm: A Multinational Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy And Safety Study Of Oral Mdv3100 In Patients With Progressive Castration-resistant Prostate Cancer Previously Treated With Docetaxel Based Chemotherapy\n",
      "Phase 3 start date: 09/30/2009\n",
      "Interventions for study: Enzalutamide; Placebo\n",
      "\n",
      "\n",
      "Querying ['bezlotoxumab', 'mdx-1388', 'mk-6072', 'mdx1388', 'mk6072', 'cdb1', 'mdx 1388', 'mk 6072', 'zinplava'] for Zinplava\n",
      "\n",
      " 14 Trials found for Zinplava\n",
      "\n",
      " No Phase 1 Data found for Zinplava\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody to Clostridium Difficile Toxin A (GS-CDA1) and a Human Monoclonal Antibody to Clostridium Difficile Toxin B (MDX-1388) in Patients Being Treated for Clostridium Difficile Associated Disease\n",
      "Phase 2 start date: 07/20/2006\n",
      "Interventions for study: GS-CDA1/MDX-1388; normal saline\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of the Efficacy, Safety, and Tolerability of a Single Infusion of MK-3415 (Human Monoclonal Antibody to Clostridium Difficile Toxin A), MK-6072 (Human Monoclonal Antibody to Clostridium Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to Clostridium Difficile Toxin A and Toxin B) in Patients Receiving Antibiotic Therapy for Clostridium Difficile Infection (MODIFY I)\n",
      "Phase 3 start date: 10/10/2011\n",
      "Interventions for study: MK-3415; MK-3415A; MK-6072; Placebo; SOC\n",
      "\n",
      "\n",
      "Querying ['larotrectinib', 'arry470', 'arry 470', 'arry-470', 'loxo101', 'loxo-101', 'loxo 101', 'bay 2757556', 'bay-2757556', 'bay2757556', 'vitrakvi'] for Vitrakvi\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " 15 Trials found for Vitrakvi\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Phase 1 Study of the Oral TRK Inhibitor Larotrectinib in Adult Patients With Solid Tumors\n",
      "Phase 1 start date: 05/04/2014\n",
      "Interventions for study: Larotrectinib (Vitrakvi, BAY2757556)\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: Molecular Analysis for Therapy Choice (MATCH)\n",
      "Phase 2 start date: 08/12/2015\n",
      "Interventions for study: Adavosertib; Afatinib; Afatinib Dimaleate; Binimetinib; Biopsy; Capivasertib; Computed Tomography; Copanlisib; Copanlisib Hydrochloride; Crizotinib; Cytology Specimen Collection Procedure; Dabrafenib; Dabrafenib Mesylate; Dasatinib; Defactinib; Defactinib Hydrochloride; Erdafitinib; FGFR Inhibitor AZD4547; Ipatasertib; Laboratory Biomarker Analysis; Larotrectinib; Larotrectinib Sulfate; Magnetic Resonance Imaging; Nivolumab; Osimertinib; PI3K-beta Inhibitor GSK2636771; Palbociclib; Pertuzumab; Relatlimab; Sapanisertib; Sunitinib Malate; Taselisib; Trametinib; Trastuzumab; Trastuzumab Emtansine; Ulixertinib; Vismodegib\n",
      "\n",
      " No Phase 3 Data found for Vitrakvi\n",
      "\n",
      "\n",
      "Querying ['horizant', '1838262', 'asp8825', 'asp-8825', 'asp 8825', 'gabapentin enacarbil', 'solzira', 'xp13512', 'gsk 1838262', 'gsk1838262', 'gsk-1838262', 'gabapentin-xp', 'xp 13512', 'xp-13512', 'regnite'] for Regnite\n",
      "\n",
      " 27 Trials found for Regnite\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: Pharmacokinetic (PK) Study of ASP8825 - Evaluation of Pharmacokinetics in Patients With Impaired Renal Function and Haemodialysis\n",
      "Phase 1 start date: 02/01/2008\n",
      "Interventions for study: ASP8825\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study to Assess the Efficacy, Safety, and Pharmacokinetics of XP13512 (GSK1838262) in Patients With Restless Legs Syndrome\n",
      "Phase 2 start date: 01/01/2007\n",
      "Interventions for study: GEn (XP13512/GSK1838262); Placebo\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XP13512 in Patients With Restless Legs Syndrome.\n",
      "Phase 3 start date: 03/01/2006\n",
      "Interventions for study: XP13512 (GSK1838262); placebo\n",
      "\n",
      "\n",
      "Querying ['siltuximab', 'cllb8', 'cnto 328', 'cnto-328', 'cnto328', 'cclb8', 'sylvant'] for Sylvant\n",
      "\n",
      " 30 Trials found for Sylvant\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Phase 1 Study of Multiple Intravenous Administrations of a Chimeric Antibody Against Interleukin-6 (CNTO 328) in Subjects With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease\n",
      "Phase 1 start date: 05/01/2005\n",
      "Interventions for study: CNTO 328\n",
      "\n",
      " No Phase 2 Data found for Sylvant\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Phase 3, Randomized, Double-blind Study of Siltuximab (Anti-IL-6 Monoclonal Antibody) or Placebo in Combination With VELCADE and Dexamethasone for the Treatment of Subjects With Relapsed or Refractory Multiple Myeloma\n",
      "Phase 3 start date: 07/01/2011\n",
      "Interventions for study: Placebo, Velcade and dexamethasone; Siltuximab, Velcade and dexamethasone\n",
      "\n",
      "\n",
      "Querying ['vericiguat', 'mk1242', 'bay 102', 'bay-102', 'bay102', 'mk-1242', 'who 9805', 'who9805', 'who-9805', 'mk 1242', 'verquvo'] for Verquvo\n",
      "\n",
      " 13 Trials found for Verquvo\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: Investigation of Pharmacokinetics, Safety, Tolerability and Pharmacodynamic Effects of BAY1021189 in Male and Female Subjects With Renal Impairment and in Age-, Gender-, and Weight-matched Healthy Subjects Following a Single Oral Dose of 2.5 mg BAY1021189 in a Single-center, Non Randomized, Non-controlled, Non-blinded, Observational Study With Group Stratification\n",
      "Phase 1 start date: 06/12/2014\n",
      "Interventions for study: Vericiguat (BAY1021189)\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure and Preserved Ejection Fraction (HFpEF)\n",
      "Phase 2 start date: 11/06/2013\n",
      "Interventions for study: Placebo; Vericiguat (BAY1021189) (1.25 mg); Vericiguat (BAY1021189) (5 mg)\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi-Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) - VerICiguaT GlObal Study in Subjects With Heart Failure With Reduced EjectIon FrAction (VICTORIA)\n",
      "Phase 3 start date: 09/20/2016\n",
      "Interventions for study: Placebo for vericiguat; Vericiguat\n",
      "\n",
      "\n",
      "Querying ['nonacog beta pegol', 'glycopegylated rfix', 'nn 7999', 'nn-7999', 'nn7999', 'rebinyn', 'refixia', 'peg-rfix', 'nnc-0156', 'nnc0156', 'nnc 0156', 'refixia'] for Refixia\n",
      "\n",
      " 10 Trials found for Refixia\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Multi-Centre, Multi-National, Open-Label, Dose Escalation Trial Evaluating Safety and Pharmacokinetics of Ascending Intravenous Doses of 40K Pegylated Recombinant FIX in Non-Bleeding Patients With Haemophilia B.\n",
      "Phase 1 start date: 08/01/2009\n",
      "Interventions for study: nonacog beta pegol\n",
      "\n",
      " No Phase 2 Data found for Refixia\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Multi-centre, Single-blind Trial Evaluating Safety and Efficacy, Including Pharmacokinetics, of NNC-0156-0000-0009 When Used for Treatment and Prophylaxis of Bleeding Episodes in Patients With Haemophilia B\n",
      "Phase 3 start date: 04/27/2011\n",
      "Interventions for study: nonacog beta pegol\n",
      "\n",
      "\n",
      "Querying ['remdesivir', 'redyx', 'gs 5734', 'gs5734', 'gs-5734', 'veklury'] for Veklury\n",
      "\n",
      " 67 Trials found for Veklury\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Randomized, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and in Combination With NA-831 in Healthy Volunteers\n",
      "Phase 1 start date: 09/15/2020\n",
      "Interventions for study: Drug: GS-5734 - 1.00 mg/kg; Drug: GS-5734 - 2.00 mg/kg; Drug: NA-831 - 0.10 mg/kg; Drug: NA-831 - 0.20 mg/kg; Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg); Drugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg); Placebo 0.10 mg + 1.00 mg/kg; Placebo 0.20 mg + 2.00 mg/kg; Placebo- 0.10 mg/kg; Placebo- 0.20 mg/kg; Placebo- 1.00 mg/kg; Placebo- 2.00 mg/kg\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: PREVAIL IV: Double-Blind, Randomized, Two-Phase, Placebo-Controlled, Phase II Trial of GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in Semen\n",
      "Phase 2 start date: 07/01/2016\n",
      "Interventions for study: GS-5734; Placebo Comparator\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir in Hospitalized Adult Patients With Severe COVID-19.\n",
      "Phase 3 start date: 02/06/2020\n",
      "Interventions for study: Remdesivir; Remdesivir placebo\n",
      "\n",
      "\n",
      "Querying ['pasireotide', 'som 230', 'som-230', 'som230', 'pashireochidopamo', 'signifor'] for Signifor\n",
      "\n",
      " 78 Trials found for Signifor\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Phase I, Multicenter, Open-label, Randomized Study Assessing the Pharmacokinetics, Safety, and Tolerability of Monthly Doses of Pasireotide i.m. LAR Injection in Patients With Acromegaly and Patients With Carcinoid Disease\n",
      "Phase 1 start date: 06/01/2006\n",
      "Interventions for study: Pasireotide\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: An Open-label, Multicenter, Phase II Study Evaluating the Safety and Efficacy of Twice Daily Dosing of SOM230 in Patients With Metastatic Carcinoid Tumors\n",
      "Phase 2 start date: 01/01/2004\n",
      "Interventions for study: Pasireotide (SOM230)\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Randomized, Double-blind Study to Assess the Safety and Efficacy of Different Dose Levels of Pasireotide (SOM230) Subcutaneous (sc) Over a 6 Month Treatment Period in Patients With de Novo, Persistent or Recurrent Cushing's Disease\n",
      "Phase 3 start date: 12/01/2006\n",
      "Interventions for study: Pasireotide\n",
      "\n",
      "\n",
      "Querying ['alirocumab', 'regn727', 'sar236553', 'regn-727', 'sar-236553', 'regn 727', 'sar 236553', 'anti-pcsk9', 'praluent'] for Praluent\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " 83 Trials found for Praluent\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Randomized,Double-Blind,Placebo-Controlled,Ascending,Single-Dose Study of the Safety,Tolerability and Bioeffect of Intravenously Administered REGN727 in Healthy Volunteers\n",
      "Phase 1 start date: 11/01/2009\n",
      "Interventions for study: Placebo; REGN727\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: A Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed Dose/Dose Regimen, Multicenter Study Evaluating the Efficacy and Safety of SAR236553 When Co-administered With 80 mg of Atorvastatin Over 8 Weeks in Patients With Primary Hypercholesterolemia and LDL-cholesterol ≥ 100 mg/dL (≥2.59 mmol/L) on Atorvastatin 10 mg\n",
      "Phase 2 start date: 01/01/2011\n",
      "Interventions for study: Alirocumab; Atorvastatin; Placebo (for alirocumab); Placebo (for atorvastatin)\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: Long-term Safety and Tolerability of SAR236553 (REGN727) in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid Modifying Therapy: A Randomized, Double-Blind, Placebo-Controlled Study\n",
      "Phase 3 start date: 01/01/2012\n",
      "Interventions for study: Alirocumab; Lipid-Modifying Therapy (LMT); Placebo (for alirocumab)\n",
      "\n",
      "\n",
      "Querying ['simponi', 'golimumab', 'cnto 148', 'cnto-148', 'cnto148', 'mk-8259', 'mk8259', 'mk 8259', 'sch 900259', 'sch900259', 'sch-900259', 'shinponi', 'sympony', 'symposony', 'xinpini', 'simponi aria'] for Simponi Aria\n",
      "\n",
      " 105 Trials found for Simponi Aria\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: An Open-label Randomized Phase 1 Study to Investigate the Pharmacokinetics and Pharmacodynamics of Subcutaneous and Intravenous Administrations of Golimumab to Subjects With Rheumatoid Arthritis\n",
      "Phase 1 start date: 12/26/2007\n",
      "Interventions for study: Golimumab\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: A Randomized, Double-blind, Dose-ranging Trial of CNTO 148 Subcutaneous Injection Compared With Placebo in Subjects With Active Rheumatoid Arthritis Despite Treatment With Methotrexate\n",
      "Phase 2 start date: 11/01/2003\n",
      "Interventions for study: Golimumab; Infliximab; MTX; Placebo\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFalpha MonoclonalAntibody, Administered Subcutaneously, in Subjects With Active Ankylosing Spondylitis\n",
      "Phase 3 start date: 12/01/2005\n",
      "Interventions for study: Golimumab (CNTO 148); placebo; golimumab\n",
      "\n",
      "\n",
      "Querying ['dulaglutide', 'ly-2189265', 'ly2189265', 'ly 2189265', 'trulicity'] for Trulicity\n",
      "\n",
      " 85 Trials found for Trulicity\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Study to Evaluate the Effect of LY2189265 on Gastric Emptying Using Scintigraphy in Patients With Type 2 Diabetes Mellitus\n",
      "Phase 1 start date: 09/01/2010\n",
      "Interventions for study: LY2189265; Placebo\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: The Effect of Dose Titration of LY2189265 in Overweight and Obese Patients With Type 2 Diabetes Mellitus\n",
      "Phase 2 start date: 04/01/2008\n",
      "Interventions for study: LY2189265; Placebo\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)\n",
      "Phase 3 start date: 02/01/2010\n",
      "Interventions for study: Exenatide; LY2189265; Metformin; Pioglitazone; Placebo\n",
      "\n",
      "\n",
      "Querying ['venetoclax', 'gdc 0199', 'abt 199', 'abt-199', 'abt199', 'gdc-0199', 'gdc0199', 'rg-7601', 'rg7601', 'rg 7601', 'venclyxto', 'ro-5537382', '1195425', 'ro5537382', 'ro 5537382', 'abt 0199', 'abt-0199', 'abt0199', 'venclexta'] for Venclexta\n",
      "\n",
      " 409 Trials found for Venclexta\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma\n",
      "Phase 1 start date: 05/23/2011\n",
      "Interventions for study: ABT-199\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: Phase II Study of Hyper-CVAD Plus Nelarabine in Previously Untreated T-ALL and Lymphoblastic Lymphoma\n",
      "Phase 2 start date: 07/11/2007\n",
      "Interventions for study: Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin Hydrochloride; Mercaptopurine; Methotrexate; Nelarabine; Pegaspargase; Prednisone; Venetoclax; Vincristine Sulfate\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Multicenter, Phase III, Open-Label, Randomized Study in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia to Evaluate the Benefit of Venetoclax (GDC-0199/ABT-199) Plus Rituximab Compared With Bendamustine Plus Rituximab\n",
      "Phase 3 start date: 03/17/2014\n",
      "Interventions for study: Bendamustine; Rituximab; Venetoclax\n",
      "\n",
      "\n",
      "Querying ['peficitinib', 'asp-015k', 'asp015k', 'asp 015k', 'jnj-54781532', 'jnj54781532', 'jnj 54781532', 'smyraf'] for Smyraf\n",
      "\n",
      " 33 Trials found for Smyraf\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP015K Following Single Oral Doses to Healthy Volunteers\n",
      "Phase 1 start date: 07/01/2008\n",
      "Interventions for study: ASP015K; Placebo\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: A Phase 2a, Randomized, Double-blind, Placebo-Controlled, Sequential Group, Multiple-Dose Escalation Study to Evaluate the Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Plaque Psoriasis\n",
      "Phase 2 start date: 03/23/2010\n",
      "Interventions for study: Placebo; peficitinib\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: Open-label Extension Study in Rheumatoid Arthritis Patients Who Have Completed Phase 2b Study or Phase 3 Study of ASP015K\n",
      "Phase 3 start date: 06/13/2012\n",
      "Interventions for study: Peficitinib\n",
      "\n",
      "\n",
      "Querying ['alpelisib', 'alpericive', 'byl 719', 'byl-719', 'byl719', 'vijoice', 'piqray'] for Piqray\n",
      "\n",
      " 89 Trials found for Piqray\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Phase IA, Multicenter, Open-label Dose Escalation Study of Oral BYL719, in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene\n",
      "Phase 1 start date: 10/05/2010\n",
      "Interventions for study: BYL719; Fulvestrant\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: A Phase Ib/II Multi-center, Open-label, Dose Escalation Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in Patients With BRAF Mutant Metastatic Colorectal Cancer\n",
      "Phase 2 start date: 11/23/2012\n",
      "Interventions for study: BYL719; Cetuximab; LGX818\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment\n",
      "Phase 3 start date: 07/23/2015\n",
      "Interventions for study: Alpelisib; Alpelisib placebo; Fulvestrant\n",
      "\n",
      "\n",
      "Querying ['rylaze', 'asparaginase escherichia coli', 'asparaginase e coli', 'colaspase', 'asparaginase e. coli', 'asnase', 'mc1003', 'mc 1003', 'mc-1003', 'mc0707', 'mc-0707', 'mc 0707', 'spectrila'] for Spectrila\n",
      "\n",
      " 2 Trials found for Spectrila\n",
      "\n",
      " No Phase 1 Data found for Spectrila\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: A Clinical Phase II Trial to Describe Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of Spectrila® With the Pharmaceutical Active Ingredient Recombinant L-Asparaginase in Adult Subjects With Newly Diagnosed Acute B-Cell Lymphoblastic Leukaemia\n",
      "Phase 2 start date: 04/26/2019\n",
      "Interventions for study: Spectrila®\n",
      "\n",
      " No Phase 3 Data found for Spectrila\n",
      "\n",
      "\n",
      "Querying ['ipragliflozin', 'asp-1941', 'asp1941', 'asp 1941', 'suglat'] for Suglat\n",
      "\n",
      " 55 Trials found for Suglat\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Double-blind, Placebo-controlled, Dose Escalating Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food-effect of Single Oral Doses of ASP1941 in Healthy Male Subjects\n",
      "Phase 1 start date: 11/01/2006\n",
      "Interventions for study: ASP1941; Placebo\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: ASP1941 Phase II Clinical Study - A Double-blind, Placebo-controlled, Parallel-group, Dose-response Study in Patients With Type 2 Diabetes Mellitus\n",
      "Phase 2 start date: 03/26/2008\n",
      "Interventions for study: Placebo; ipragliflozin\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: Phase III Study of ASP1941 -A Phase III, Randomized, Double-Blind, Placebo-controlled, Monotherapy Study to Assess the Efficacy, Safety, and Tolerability of ASP1941 in Japanese Patients With Type 2 Diabetes Mellitus\n",
      "Phase 3 start date: 01/13/2010\n",
      "Interventions for study: ipragliflozin; placebo\n",
      "\n",
      "\n",
      "Querying ['somapacitan', 'nn-8640', 'nn8640', 'nnc-0195-0092', 'nnc0195-0092', 'nn 8640', 'sogroya'] for Sogroya\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " 16 Trials found for Sogroya\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: First Human Dose Trial of NNC0195-0092 (Somapacitan) in Healthy Subjects\n",
      "Phase 1 start date: 01/16/2012\n",
      "Interventions for study: placebo (somapacitan); somapacitan\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: A Randomised, Multinational, Active-controlled, (Open-labelled), Dose Finding, (Double-blinded), Parallel Group Trial Investigating Efficacy and Safety of Once-weekly NNC0195-0092 Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency\n",
      "Phase 2 start date: 03/23/2016\n",
      "Interventions for study: Norditropin® FlexPro® pen; somapacitan\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Multicentre, Multinational, Randomised, Parallel-group, Placebo-controlled (Double Blind) and Active-controlled (Open) Trial to Compare the Efficacy and Safety of Once Weekly Dosing of NNC0195-0092 (Somapacitan) With Once Weekly Dosing of Placebo and Daily Norditropin® FlexPro® in Adults With Growth Hormone Deficiency for 35 Weeks, Followed by a 53-week Open-label Extension Period\n",
      "Phase 3 start date: 10/31/2014\n",
      "Interventions for study: placebo; somapacitan; somatropin\n",
      "\n",
      "\n",
      "Querying ['tr-701', 'tr701', 'tr 701', 'torezolid', 'tedizolid', 'mk-1986', 'mk1986', 'mk 1986', 'bay 1192631', 'bay1192631', 'bay-1192631', 'da-70157', 'da-70218', 'da-7157', 'da-7218', 'da 70157', 'da 70218', 'da 7157', 'da 7218', 'da70157', 'da70218', 'da7157', 'da7218', 'sivextro'] for Sivextro\n",
      "\n",
      " 37 Trials found for Sivextro\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Double-Blind, Placebo and Active Controlled, Single and Multiple Rising Dose, Safety, Tolerance, and Pharmacokinetic Study of TR-701 in Normal Healthy Adults\n",
      "Phase 1 start date: 01/06/2008\n",
      "Interventions for study: TR-701; linezolid; placebo\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: A Phase 2 Multi-Center, Randomized, Double-Blind, Non-Controlled Study Comparing the Safety, Tolerance, and Efficacy of TR-701 in Patients With Complicated Skin and Skin Structure Infections\n",
      "Phase 2 start date: 09/17/2008\n",
      "Interventions for study: TR-701 200 mg; TR-701 300 mg; TR-701 400 mg\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Phase 3 Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of 6-Day Oral TR-701 Free Acid and 10-Day Oral Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections\n",
      "Phase 3 start date: 08/15/2010\n",
      "Interventions for study: Linezolid; TR-701 FA\n",
      "\n",
      "\n",
      "Querying ['casirivimab/imdevimab', 'imdevimab/casirivimab', 'regn cov', 'regn-cov', 'regncov', 'regn10933-10987', 'regn10987-10933', 'ronapreve'] for Ronapreve\n",
      "\n",
      " 0 Trials found for Ronapreve\n",
      "\n",
      " No Phase 1 Data found for Ronapreve\n",
      "\n",
      " No Phase 2 Data found for Ronapreve\n",
      "\n",
      " No Phase 3 Data found for Ronapreve\n",
      "\n",
      "\n",
      "Querying ['dabrafenib', 'drb 436', 'drb436', 'drb-436', 'taffiner', 'tafinra', 'tafinrar', '2118436', 'tafinlar'] for Tafinlar\n",
      "\n",
      " 132 Trials found for Tafinlar\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Phase I, Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of the BRAF Inhibitor GSK2118436 in Subjects With Solid Tumors\n",
      "Phase 1 start date: 06/04/2009\n",
      "Interventions for study: GSK2118436; Midazolam\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the BRAF Inhibitor GSK2118436 in Combination With the MEK Inhibitor GSK1120212 in Subjects With BRAF Mutant Metastatic Melanoma\n",
      "Phase 2 start date: 03/26/2010\n",
      "Interventions for study: GSK1120212; GSK2118436\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma\n",
      "Phase 3 start date: 12/23/2010\n",
      "Interventions for study: Dacarbazine (DTIC); GSK2118436\n",
      "\n",
      "\n",
      "Querying ['axicabtagene', 'kte-c19', 'ktec19', 'kte c19', 'yikaida', 'fkc 876', 'fkc-876', 'fkc876', 'yescarta'] for Yescarta\n",
      "\n",
      " 24 Trials found for Yescarta\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Phase 1/2 Multi-center Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Subjects With Relapsed/Refractory Large B-Cell Lymphoma\n",
      "Phase 1 start date: 11/20/2018\n",
      "Interventions for study: Axicabtagene Ciloleucel; Cyclophosphamide; Fludarabine; Utomilumab\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects With Relapsed/Refractory Mantle Cell Lymphoma\n",
      "Phase 2 start date: 11/09/2015\n",
      "Interventions for study: Axicabtagene Ciloleucel; Cyclophosphamide; Fludarabine; brexucabtagene autoleucel\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Phase 3, Randomized, Open-Label Study Evaluating Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma\n",
      "Phase 3 start date: 01/25/2018\n",
      "Interventions for study: Axicabtagene Ciloleucel; Cyclophosphamide; Fludarabine; Platinum-containing salvage chemotherapy (eg, R-ICE) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders.\n",
      "\n",
      "\n",
      "Querying ['sirolimus', 'cypher', 'hyftor', 'nevo', 'npc-12', 'npc12', 'npc 12', 'ay 22989', 'ay-22989', 'ay22989', 'nsc 226080', 'nsc-226080', 'nsc226080', 'nsc 606698', 'nsc-606698', 'nsc606698', 'rapamune', 'rapamycin', 'rapalimus'] for Rapalimus\n",
      "\n",
      " 951 Trials found for Rapalimus\n",
      "\n",
      " No Phase 1 Data found for Rapalimus\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: A Phase II, Open-Label, Concentration-Controlled, Randomized, 6-Month Study of 'Standard Dose' Tacrolimus + Sirolimus + Corticosteroids Compared to 'Reduced Dose' Tacrolimus + Sirolimus + Corticosteroids in Renal Allograft Recipients\n",
      "Phase 2 start date: 04/01/2000\n",
      "Interventions for study: Corticosteroids; Rapamune® (Sirolimus); Tacrolimus\n",
      "\n",
      " No Phase 3 Data found for Rapalimus\n",
      "\n",
      "\n",
      "Querying ['insulin decludec', 'nn-1250', 'nn1250', 'nn 1250', 'tresiba'] for Tresiba\n",
      "\n",
      " 5 Trials found for Tresiba\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: Pharmacokinetics, Pharmacodynamic, Safety and Immunogenicity Characteristics of Insulin Degludec Injection (RD15003) and Insulin Degludec Injection ( Tresiba®）in Healthy Subjects: a Phase I Single-center, Randomized, Open-label, Single-dose, Cross-over Clinical Study\n",
      "Phase 1 start date: 10/08/2021\n",
      "Interventions for study: Insulin degludec injection, RD15003; Insulin degludec, Tresiba\n",
      "\n",
      " No Phase 2 Data found for Tresiba\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Multicenter, Randomized, Open-label, Parallel-controlled Phase III Clinical Study to Compare the Efficacy and Safety of Insulin Degludec Injection Versus Tresiba® in Subjects With Type 2 Diabetes\n",
      "Phase 3 start date: 07/27/2021\n",
      "Interventions for study: Insulin degludec injection; Tresiba®\n",
      "\n",
      "\n",
      "Querying ['degludecplus', 'insulin degludec/insulin aspart', 'insulin aspart/insulin degludec', 'idegasp', 'nn1045', 'nn 1045', 'nn-1045', 'nn5401', 'nn-5401', 'nn 5401', 'ryzodeg'] for Ryzodeg\n",
      "\n",
      " 44 Trials found for Ryzodeg\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Randomised, Double-blind, Multiple Period Crossover Trial Comparing Insulin 454 and Insulin Aspart Premixes With Separately Injected, Simultaneous Doses of Insulin 454 and Insulin Aspart, Compared With Biphasic Insulin Aspart 30 (NovoMix® 30) in Male Subjects With Type 1 and Type 2 Diabetes Mellitus\n",
      "Phase 1 start date: 09/01/2006\n",
      "Interventions for study: biphasic insulin aspart 30; insulin aspart; insulin degludec; insulin degludec/insulin aspart 30; insulin degludec/insulin aspart 40; insulin degludec/insulin aspart 50\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: A 16 Week Randomised, Open Labelled, 3 Armed, Parallel Group, Treat-to-target Trial Comparing Once Daily Injection of SIAC 30 (B), SIAC 45 (B) and Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes Failing on OAD Treatment\n",
      "Phase 2 start date: 01/01/2008\n",
      "Interventions for study: insulin degludec/insulin aspart; insulin glargine; metformin\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: NN5401-3594: A 26-week, Open-labelled, Two-arm, Parallel, Randomised Trial Comparing Efficacy and Safety of NN5401 Once Daily Plus Insulin Aspart vs. Basal-bolus Treatment With Insulin Detemir Plus Insulin Aspart in Subjects With Type 1 Diabetes / NN5401-3645: An Extension Trial Comparing Safety and Efficacy of NN5401 Plus Meal-time Insulin Aspart for the Remaining Meals With Insulin Detemir Plus Meal-time Insulin Aspart in Type 1 Diabetes (BOOST™: T1)\n",
      "Phase 3 start date: 08/01/2009\n",
      "Interventions for study: insulin aspart; insulin degludec/insulin aspart; insulin detemir\n",
      "\n",
      "\n",
      "Querying ['baricitinib', 'incb 028050', 'incb 28050', 'ly 3009104', 'ly3009104', 'incb028050', 'ly-3009104', 'incb-028050', 'incb-28050', 'incb28050', 'olumiant'] for Olumiant\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " 110 Trials found for Olumiant\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Single- and Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3009104 in Japanese Healthy Subjects\n",
      "Phase 1 start date: 11/01/2010\n",
      "Interventions for study: LY3009104; Placebo\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: A Randomized, Double-blind, Placebo Controlled, Dose Ranging, Parallel Group, Phase 2 Study of INCB028050 Compared to Background Therapy in Patients With Active RA With Inadequate Response to Any Disease Modifying Anti-Rheumatic Drugs (DMARD) Therapy Including Biologics\n",
      "Phase 2 start date: 05/01/2009\n",
      "Interventions for study: INCB028050; Placebo\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response\n",
      "Phase 3 start date: 08/01/2007\n",
      "Interventions for study: Abatacept; Adalimumab; Azathioprine; Baricitinib; Certolizumab; Etanercept; Golimumab; Hydroxychloroquine; Infliximab; Leflunomide; Methotrexate; Minocycline; Rituximab; Sarilumab; Sulfasalazine; Tofacitinib\n",
      "\n",
      "\n",
      "Querying ['onasemnogene abeparvovec', 'avxs 101', 'avxs-101', 'avxs101', 'charisma', 'oav-101', 'oav101', 'oav 101', 'onasemnogene abeparvovec', 'zolgensma'] for Zolgensma\n",
      "\n",
      " 18 Trials found for Zolgensma\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: Phase I Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1 Delivering AVXS-101\n",
      "Phase 1 start date: 05/05/2014\n",
      "Interventions for study: AVXS-101\n",
      "\n",
      " No Phase 2 Data found for Zolgensma\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion\n",
      "Phase 3 start date: 10/24/2017\n",
      "Interventions for study: Onasemnogene Abeparvovec-xioi\n",
      "\n",
      "\n",
      "Querying ['vigadrone', 'vigabatrin', 'cpp-109', 'cpp109', 'mdl 71,754', 'mdl-71754', 'rmi-71754', 'cpp 109', 'mdl71,754', 'mdl71754', 'rmi71754', 'mdl 71754', 'rmi 71754', 'm071754', 'm-071754', 'sabrilex', 'sabril'] for Sabril\n",
      "\n",
      " 25 Trials found for Sabril\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Intravenous Cocaine and Oral Gamma Vinyl-Gamma-Amino Butyric Acid (VIGABATRIN) Interaction Study\n",
      "Phase 1 start date: 02/01/2008\n",
      "Interventions for study: Matching placebo; Vigabatrin\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: Effects of Vigabatrin on Cocaine Self-Administration\n",
      "Phase 2 start date: 04/01/2006\n",
      "Interventions for study: Cocaine; Vigabatrin\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: Prednisolone vs. Vigabatrin in the First-line Treatment of Infantile Spasms\n",
      "Phase 3 start date: 09/05/2017\n",
      "Interventions for study: Prednisolone; Vigabatrin\n",
      "\n",
      "\n",
      "Querying ['tigecycline', 'cl-329998', 'cl329998', 'cl 329998', 'cl-331002', 'cl331002', 'cl 331002', 'dmg-dmdot', 'dmg-mino', 'gar 936', 'gar-936', 'tbg-mino', 'gar936', 'way 156936', 'way156936', 'way-156936', 'tygacil'] for Tygacil\n",
      "\n",
      " 55 Trials found for Tygacil\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: An Open-Label, Multiple-Dose Study of the Pharmacokinetics of Tigecycline in Human Bone\n",
      "Phase 1 start date: 09/01/2006\n",
      "Interventions for study: Tigecycline\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: Use of Tigecycline for Treatment of Serious Infection Due to Rapidly Growing Mycobacteria (Especially M.Abscessus)\n",
      "Phase 2 start date: 04/01/2002\n",
      "Interventions for study: Tigecycline\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Multicenter, Randomized, Double-Blind Comparison of the Safety and Efficacy of Tigecycline With Those of Vancomycin With Aztreonam to Treat Complicated Skin and Skin Structure Infections in Hospitalized Patients.\n",
      "Phase 3 start date: 11/01/2002\n",
      "Interventions for study: Tigecycline; vancomycin with aztreonam\n",
      "\n",
      "\n",
      "Querying ['bedaquiline', 'aids222089', 'r 207910', 'r-207910', 'r207910', 'tmc 207', 'tmc-207', 'tmc207', 'aids-222089', 'aids 222089', 'r 403323', 'r403323', 'r-403323', 'sirturo'] for Sirturo\n",
      "\n",
      " 57 Trials found for Sirturo\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Phase I, Open-label, Randomized Crossover Trial to Investigate the Pharmacokinetic Interaction Between Steady-state Lopinavir/Ritonavir and Single-dose TMC207 in Healthy Subjects.\n",
      "Phase 1 start date: 02/01/2009\n",
      "Interventions for study: TMC207\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: An Open-label Study to Evaluate the Extended Early Bactericidal Activity, Safety, Tolerability and Pharmacokinetics of Multiple Oral Doses of TMC207 in Treatment-na�ve Subjects With Sputum Smear Positive Pulmonary Tuberculosis.\n",
      "Phase 2 start date: 05/01/2005\n",
      "Interventions for study: TMC207\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Phase III Placebo-controlled, Double-blind, Randomized Trial to Evaluate the Efficacy and Safety of TMC207 in Subjects With Sputum Smear-positive Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB)\n",
      "Phase 3 start date: 03/01/2014\n",
      "Interventions for study: Arm A Double-blind Phase: TMC207; Arm B Double-blind Phase: Placebo; Treatment Failure During Double-blind Phase: TMC207; Treatment Failure During Follow-up Phase: TMC207\n",
      "\n",
      "\n",
      "Querying ['lumefantrine/artemether', 'artemether/lumefantrine', 'benflumetol', 'cgp 56697', 'cgp56697', 'cgp-56697', 'coa566', 'coartem', 'exafal', 'coa-566', 'coa 566', 'riamet'] for Riamet\n",
      "\n",
      " 37 Trials found for Riamet\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: Pharmacokinetic Interactions Between Antiretroviral Agents, Lopinavir/Ritonavir and Efavirenz and Antimalarial Drug Combinations, Artesunate/Amodiaquine and Artemether/Lumefantrine.\n",
      "Phase 1 start date: 07/01/2005\n",
      "Interventions for study: artemether/lumefantrine; efavirenz; lopinavir/ritonavir\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: Phase 2 Proof of Concept Study of a Candidate Aminoquinoline Antimalarial (AQ-13)\n",
      "Phase 2 start date: 08/01/2013\n",
      "Interventions for study: AQ-13 Treatment; Coartem Treatment\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: Randomized Trial of the Safety and Effectiveness of Lapdap and Coartemether for Uncomplicated Malaria in Operational Settings\n",
      "Phase 3 start date: 09/01/2004\n",
      "Interventions for study: Chlorproguanil-dapsone (Lapdap); Lumefantrine-artemether (Coartemether )\n",
      "\n",
      "\n",
      "Querying ['abemaciclib', 'ly 2835219', 'ly-2835219', 'ly2835219', 'bemaciclib', 'verzenio'] for Verzenio\n",
      "\n",
      " 162 Trials found for Verzenio\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Phase 1 Study of a CDK 4/6 Dual Inhibitor in Participants With Advanced Cancer\n",
      "Phase 1 start date: 12/07/2009\n",
      "Interventions for study: Fulvestrant; LY2835219\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)\n",
      "Phase 2 start date: 03/01/2010\n",
      "Interventions for study: ABT-888; AMG 386 and Trastuzumab; AMG 386 with or without Trastuzumab; AMG 479 (Ganitumab) plus Metformin; ARX788; ARX788 + Cemiplimab; Amcenestrant; Amcenestrant + Abemaciclib; Amcenestrant + Letrozole; Cemiplimab; Cemiplimab plus REGN3767; Datopotamab deruxtecan; Datopotamab deruxtecan + Durvalumab; Durvalumab plus Olaparib; Ganetespib; MK-2206 with or without Trastuzumab; Neratinib; Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab; Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab; PLX3397; Patritumab and Trastuzumab; Pembrolizumab - 4 cycle; Pembrolizumab - 8 cycle; Pertuzumab and Trastuzumab; SD-101 + Pembrolizumab; SGN-LIV1A; SYD985 ([vic-]trastuzumab duocarmazine); Standard Therapy; T-DM1 and Pertuzumab; Talazoparib plus Irinotecan; Trilaciclib with or without trastuzumab + pertuzumab; Tucatinib plus trastuzumab and pertuzumab; VV1 + Cemiplimab\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: MONARCH 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant With or Without Abemaciclib, a CDK4/6 Inhibitor, for Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer\n",
      "Phase 3 start date: 07/22/2014\n",
      "Interventions for study: Abemaciclib; Fulvestrant; Placebo\n",
      "\n",
      "\n",
      "Querying ['isatuximab', 'hu-38sb19', 'hu 38sb19', 'sar 650984', 'sar-650984', 'sar650984', 'hu38sb19', 'sarclisa'] for Sarclisa\n",
      "\n",
      " 65 Trials found for Sarclisa\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Phase 1b Study of SAR650984 (Anti-CD38 mAb) in Combination With Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma\n",
      "Phase 1 start date: 02/06/2013\n",
      "Interventions for study: dexamethasone; isatuximab SAR650984; lenalidomide\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: Phase II Single Arm Trial of Isatuximab (SAR650984) in Patients With High Risk Smoldering Multiple Myeloma\n",
      "Phase 2 start date: 02/08/2017\n",
      "Interventions for study: Isatuximab; Laboratory Biomarker Analysis\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Phase 3 Randomized, Open-label, Multicenter Study Comparing Isatuximab (SAR650984) in Combination With Pomalidomide and Low-Dose Dexamethasone Versus Pomalidomide and Low-Dose Dexamethasone in Patients With Refractory or Relapsed and Refractory Multiple Myeloma\n",
      "Phase 3 start date: 12/22/2016\n",
      "Interventions for study: Dexamethasone; Isatuximab; Pomalidomide\n",
      "\n",
      "\n",
      "Querying ['aflibercept', 'ave 0005', 'ave 005', 'ave-0005', 'ave0005', '86-5321', '865321', 'ave005', 'ave-005', 'eylea', 'regn3', 'wetlia', 'zaltrap'] for Zaltrap\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " 417 Trials found for Zaltrap\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: An Open-Label, Sequential Cohort Dose-Escalation Safety, Tolerability And Pharmacokinetic Study Of VEGF Trap In Patients With Incurable, Relapsed Or Refractory Solid Tumors Or Lymphoma\n",
      "Phase 1 start date: 11/01/2001\n",
      "Interventions for study: ziv-aflibercept\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: A Multicenter, Open-label, Single-arm, Two-stage Study of the Efficacy and Safety of AVE0005 (VEGF Trap) Administered Intravenously Every 2 Weeks in Patients With Platinum- and Erlotinib-resistant Locally Advanced or Metastatic Non-small-cell Lung Adenocarcinoma\n",
      "Phase 2 start date: 01/01/2006\n",
      "Interventions for study: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects With Neovascular Age-Related Macular Degeneration\n",
      "Phase 3 start date: 08/01/2007\n",
      "Interventions for study: aflibercept injection (VEGF Trap-Eye, BAY86-5321); ranibizumab\n",
      "\n",
      "\n",
      "Querying ['vaniprevir', 'mk 7009', 'mk-7009', 'mk7009', 'vanihep'] for Vanihep\n",
      "\n",
      " 12 Trials found for Vanihep\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Phase Ib Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of MK7009 in Hepatitis C Infected Patients\n",
      "Phase 1 start date: 07/01/2007\n",
      "Interventions for study: Comparator: MK7009; Comparator: Placebo\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: A Phase II, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MK7009 Administered Concomitantly With Pegylated-Interferon and Ribavirin for 28 Days in Treatment-Naive Patients With Chronic Hepatitis C Infection\n",
      "Phase 2 start date: 07/25/2008\n",
      "Interventions for study: Comparator: Pegylated-Interferon (Peg-IFN); Comparator: Ribavirin; Comparator: Vaniprevir; Comparator: placebo\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Phase III Randomized, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of MK-7009 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Japanese Treatment-Naïve Patients With Chronic Hepatitis C Infection\n",
      "Phase 3 start date: 06/27/2011\n",
      "Interventions for study: Peg-IFN; Placebo to vaniprevir; ribavirin; vaniprevir\n",
      "\n",
      "\n",
      "Querying ['ra 223', 'alpharadin', 'ac1o4d1m', 'ra223', 'ati-bc-1', 'ra-223', 'bay 88-8223', 'bay-88-8223', 'bay88-8223', 'xofigo'] for Xofigo\n",
      "\n",
      " 67 Trials found for Xofigo\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Phase I Open-label, Multicenter, Dose-escalating Study of Radium-223 in Patients With Advanced Skeletal Metastases\n",
      "Phase 1 start date: 08/14/2001\n",
      "Interventions for study: Radium-223 dichloride (BAY88-8223)\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: A Phase II Randomised, Placebo-controlled, Multicentre Study in Prostate Cancer Patients With Painful Bone Metastases to Evaluate the Efficacy of Repeated Radium-223 Injections\n",
      "Phase 2 start date: 02/01/2004\n",
      "Interventions for study: Radium-223 dichloride (BAY88-8223); Saline\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Double-blind, Randomised, Multiple Dose, Phase III, Multicentre Study of Alpharadin in the Treatment of Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases\n",
      "Phase 3 start date: 06/01/2008\n",
      "Interventions for study: Best standard of care (BSoC); Placebo; Radium-223 dichloride (Xofigo, BAY88-8223)\n",
      "\n",
      "\n",
      "Querying ['hydroxychloroquine', 'plaquenil'] for Plaquenil\n",
      "\n",
      " 395 Trials found for Plaquenil\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: Bioavailability of Hydroxychloroquine Sulfate, 200 mg Tablets\n",
      "Phase 1 start date: 07/01/1993\n",
      "Interventions for study: Hydroxychloroquine Sulfate Tablets, 200 mg (Geneva Pharmaceutical, Inc.); Hydroxychloroquine Sulfate Tablets, 200 mg, Plaquenil (Sanofi Winthrop)\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: Hydroxychloroquine Versus Clobetasol 0.05% Rinse for the Treatment of Oral Lichen Planus\n",
      "Phase 2 start date: 01/01/2005\n",
      "Interventions for study: Hydroxychloroquine\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: Triple III Comparison of Leflunomide Alone Versus Two DMARD Combinations (Leflunomide-Hydroxychloroquine-Sulfasalazine or Methotrexate-Hydroxychloroquine-Sulfasalazine) in the Treatment of Rheumatoid Arthritis\n",
      "Phase 3 start date: 12/01/1999\n",
      "Interventions for study: Leflunomide; Leflunomide-Sulfasalazine-Hydroxychloroquine; Methotrexate-Sulfasalazine-Hydroxychloroquine\n",
      "\n",
      "\n",
      "Querying ['rovamycin', 'foromacidine a', 'foromacidin a', 'demycarosylturimycin h', 'spiramycin'] for Spiramycin\n",
      "\n",
      " 4 Trials found for Spiramycin\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: Single-Blind Efficacy Evaluation of Intravenous Spiramycin in Subjects With AIDS-Related Cryptosporidial Diarrhea\n",
      "\n",
      " No Phase 1 Data found for Spiramycin\n",
      "\n",
      " No Phase 2 Data found for Spiramycin\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: Multicenter, Randomized Clinical Trial to Compare the Efficacy and Tolerance of Prenatal Therapy With Pyrimethamine + Sulfadiazine vs Spiramycine to Reduce Vertical Transmission of Toxoplasma Gondii Following Primary Infection in Pregnancy\n",
      "Phase 3 start date: 11/01/2010\n",
      "Interventions for study: Pyrimethamine/Sulfadiazine; Spiramycine\n",
      "\n",
      "\n",
      "Querying ['mk-5348', 'mk 5348', 'mk5348', 'sch-530348', 'sch530348', 'sch 530348', 'mfcd16038876', 'zce93644n2', 'zontivity'] for Zontivity\n",
      "\n",
      " 2 Trials found for Zontivity\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Study to Determine the Bioequivalence of SCH 530348 2.5 mg Tablets Containing a High and Low Percentage of Drug as the Free Base Within the Range Used in the Pivotal Phase 3 Efficacy and Safety Trials. (Protocol No. P06558)\n",
      "Phase 1 start date: 08/01/2010\n",
      "Interventions for study: Pantoprazole; SCH 530348 (high percentage); SCH 530348 (standard percentage)\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of SCH 530348 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention\n",
      "Phase 2 start date: 08/30/2005\n",
      "Interventions for study: SCH 530348\n",
      "\n",
      " No Phase 3 Data found for Zontivity\n",
      "\n",
      "\n",
      "Querying ['ceritinib', 'jikadia', 'ldk-378', 'ldk 378', 'ldk378', 'zykadia'] for Zykadia\n",
      "\n",
      " 45 Trials found for Zykadia\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Phase I, Multi-center, Open Label Dose Escalation Study of LDK378, Administered Orally in Adult Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK)\n",
      "Phase 1 start date: 01/24/2011\n",
      "Interventions for study: LDK378\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: A Phase II, Multicenter, Single-arm Study of Oral LDK378 in Adult Patients With ALK-activated Non-small Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib\n",
      "Phase 2 start date: 11/26/2012\n",
      "Interventions for study: LDK378\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Phase III, Multicenter, Randomized, Open-label Study of Oral LDK378 Versus Standard Chemotherapy in Adult Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer Who Have Been Treated Previously With Chemotherapy (Platinum Doublet) and Crizotinib\n",
      "Phase 3 start date: 06/28/2013\n",
      "Interventions for study: Ceritinib; docetaxel; pemetrexed\n",
      "\n",
      "\n",
      "Querying ['rhfxiii', 'rhfactor-xiii', 'rfxiii', 'factor xiii', 'catridecacog', 'nn1810', 'nn-1810', 'nn 1810', 'nn1841', 'nn-1841', 'nn 1841', 'nn8717', 'nn-8717', 'nn 8717', 'tretten'] for Tretten\n",
      "\n",
      " 17 Trials found for Tretten\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: A Randomized, Placebo-controlled Single-dose, Double-blind Study of the Safety and Pharmacokinetics of Recombinant Factor XIII in Healthy Volunteers\n",
      "Phase 1 start date: 01/01/2003\n",
      "Interventions for study: catridecacog; placebo\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: A Multi-Centre, Randomised, Double-Blind, Placebo Controlled Trial on Efficacy and Safety of FXIII Replenishment With Two Different Doses of Recombinant Factor XIII Following Cardiopulmonary Bypass Surgery\n",
      "Phase 2 start date: 07/01/2009\n",
      "Interventions for study: catridecacog; placebo\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: A Multi-Centre, Open-Label, Single-Arm and Multiple Dosing Trial on Efficacy and Safety of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Subjects With Congenital Factor XIII Deficiency\n",
      "Phase 3 start date: 08/01/2008\n",
      "Interventions for study: catridecacog\n",
      "\n",
      "\n",
      "Querying ['rivaroxaban', 'bay 59-7939', 'bay-59-7939', 'jnj-39039039', 'jnj39039039', 'jnj 39039039', 'bay597939', 'xarelto'] for Xarelto\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " 379 Trials found for Xarelto\n",
      "\n",
      "\n",
      "Title of Phase 1 initial study found: Randomized, Placebo-controlled, Parallel-group Study in Healthy Male Subjects to Investigate the Pharmacodynamics During the Switching Procedure From Warfarin to Rivaroxaban\n",
      "Phase 1 start date: 11/01/2008\n",
      "Interventions for study: Placebo; Rivaroxaban (Xarelto, BAY59-7939); Vitamin K (Konakion); Warfarin (Coumadin)\n",
      "\n",
      "\n",
      "Title of Phase 2 initial study found: Oral Direct Factor Xa Inhibitor BAY 59-7939 in the Prevention of VTE in Patients Undergoing Total Hip Replacement. ODiXahip - a Phase IIa Dose Escalating Proof of Principle Trial\n",
      "Phase 2 start date: 12/01/2002\n",
      "Interventions for study: Enoxaparin; Rivaroxaban (BAY59-7939)\n",
      "\n",
      "\n",
      "Title of Phase 3 initial study found: RECORD 3 Study: REgulation of Coagulation in ORthopedic Surgery to Prevent DVT and PE; a Controlled., Double-blind, Randomized Study of BAY 59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement.\n",
      "Phase 3 start date: 02/01/2006\n",
      "Interventions for study: Enoxaparin; Rivaroxaban (BAY59-7939)\n"
     ]
    }
   ],
   "source": [
    "test_pull = find_min_phase_dates(data, syn_data, d_index, query_mol)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "5f9a9c99",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>molecule</th>\n",
       "      <th>intervention</th>\n",
       "      <th>nct_id</th>\n",
       "      <th>title</th>\n",
       "      <th>phase</th>\n",
       "      <th>min_start_date</th>\n",
       "      <th>sponsor</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Zeposia</td>\n",
       "      <td>RPC1063</td>\n",
       "      <td>NCT02797015</td>\n",
       "      <td>A Phase I, Multicenter, Randomized, 12-Week, O...</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>2016-06-23 00:00:00</td>\n",
       "      <td>Celgene</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Zeposia</td>\n",
       "      <td>Ozanimod; Placebo</td>\n",
       "      <td>NCT01647516</td>\n",
       "      <td>A Phase 2, Multi-Center, Randomized, Double-Bl...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>2012-12-26 00:00:00</td>\n",
       "      <td>Celgene</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Zeposia</td>\n",
       "      <td>Interferon beta-1a; Interferon beta-1a placebo...</td>\n",
       "      <td>NCT02047734</td>\n",
       "      <td>A Phase 2/3, Multi-center, Randomized, Double-...</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>2013-12-03 00:00:00</td>\n",
       "      <td>Celgene</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Rybrevant</td>\n",
       "      <td>JNJ-61178104 Intravenous; JNJ-61178104 Subcuta...</td>\n",
       "      <td>NCT02758392</td>\n",
       "      <td>A Phase 1, Randomized, Double-blind, Placebo-c...</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>2016-04-01 00:00:00</td>\n",
       "      <td>Janssen Research &amp; Development, LLC</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Rybrevant</td>\n",
       "      <td>Amivantamab</td>\n",
       "      <td>NCT04945733</td>\n",
       "      <td>A Phase 2, Open-label Study of Amivantamab in ...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>2021-08-30 00:00:00</td>\n",
       "      <td>Janssen Pharmaceutical K.K.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>289</th>\n",
       "      <td>Tretten</td>\n",
       "      <td>catridecacog; placebo</td>\n",
       "      <td>NCT00914589</td>\n",
       "      <td>A Multi-Centre, Randomised, Double-Blind, Plac...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>2009-07-01 00:00:00</td>\n",
       "      <td>Novo Nordisk A/S</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>290</th>\n",
       "      <td>Tretten</td>\n",
       "      <td>catridecacog</td>\n",
       "      <td>NCT00713648</td>\n",
       "      <td>A Multi-Centre, Open-Label, Single-Arm and Mul...</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>2008-08-01 00:00:00</td>\n",
       "      <td>Novo Nordisk A/S</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>291</th>\n",
       "      <td>Xarelto</td>\n",
       "      <td>Placebo; Rivaroxaban (Xarelto, BAY59-7939); Vi...</td>\n",
       "      <td>NCT01507051</td>\n",
       "      <td>Randomized, Placebo-controlled, Parallel-group...</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>2008-11-01 00:00:00</td>\n",
       "      <td>Bayer; Johnson &amp; Johnson Pharmaceutical Resear...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>292</th>\n",
       "      <td>Xarelto</td>\n",
       "      <td>Enoxaparin; Rivaroxaban (BAY59-7939)</td>\n",
       "      <td>NCT00839826</td>\n",
       "      <td>Oral Direct Factor Xa Inhibitor BAY 59-7939 in...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>2002-12-01 00:00:00</td>\n",
       "      <td>Bayer</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>293</th>\n",
       "      <td>Xarelto</td>\n",
       "      <td>Enoxaparin; Rivaroxaban (BAY59-7939)</td>\n",
       "      <td>NCT00361894</td>\n",
       "      <td>RECORD 3 Study: REgulation of Coagulation in O...</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>2006-02-01 00:00:00</td>\n",
       "      <td>Bayer</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>294 rows × 7 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "      molecule                                       intervention  \\\n",
       "0      Zeposia                                            RPC1063   \n",
       "1      Zeposia                                  Ozanimod; Placebo   \n",
       "2      Zeposia  Interferon beta-1a; Interferon beta-1a placebo...   \n",
       "3    Rybrevant  JNJ-61178104 Intravenous; JNJ-61178104 Subcuta...   \n",
       "4    Rybrevant                                        Amivantamab   \n",
       "..         ...                                                ...   \n",
       "289    Tretten                              catridecacog; placebo   \n",
       "290    Tretten                                       catridecacog   \n",
       "291    Xarelto  Placebo; Rivaroxaban (Xarelto, BAY59-7939); Vi...   \n",
       "292    Xarelto               Enoxaparin; Rivaroxaban (BAY59-7939)   \n",
       "293    Xarelto               Enoxaparin; Rivaroxaban (BAY59-7939)   \n",
       "\n",
       "          nct_id                                              title    phase  \\\n",
       "0    NCT02797015  A Phase I, Multicenter, Randomized, 12-Week, O...  Phase 1   \n",
       "1    NCT01647516  A Phase 2, Multi-Center, Randomized, Double-Bl...  Phase 2   \n",
       "2    NCT02047734  A Phase 2/3, Multi-center, Randomized, Double-...  Phase 3   \n",
       "3    NCT02758392  A Phase 1, Randomized, Double-blind, Placebo-c...  Phase 1   \n",
       "4    NCT04945733  A Phase 2, Open-label Study of Amivantamab in ...  Phase 2   \n",
       "..           ...                                                ...      ...   \n",
       "289  NCT00914589  A Multi-Centre, Randomised, Double-Blind, Plac...  Phase 2   \n",
       "290  NCT00713648  A Multi-Centre, Open-Label, Single-Arm and Mul...  Phase 3   \n",
       "291  NCT01507051  Randomized, Placebo-controlled, Parallel-group...  Phase 1   \n",
       "292  NCT00839826  Oral Direct Factor Xa Inhibitor BAY 59-7939 in...  Phase 2   \n",
       "293  NCT00361894  RECORD 3 Study: REgulation of Coagulation in O...  Phase 3   \n",
       "\n",
       "          min_start_date                                            sponsor  \n",
       "0    2016-06-23 00:00:00                                            Celgene  \n",
       "1    2012-12-26 00:00:00                                            Celgene  \n",
       "2    2013-12-03 00:00:00                                            Celgene  \n",
       "3    2016-04-01 00:00:00                Janssen Research & Development, LLC  \n",
       "4    2021-08-30 00:00:00                        Janssen Pharmaceutical K.K.  \n",
       "..                   ...                                                ...  \n",
       "289  2009-07-01 00:00:00                                   Novo Nordisk A/S  \n",
       "290  2008-08-01 00:00:00                                   Novo Nordisk A/S  \n",
       "291  2008-11-01 00:00:00  Bayer; Johnson & Johnson Pharmaceutical Resear...  \n",
       "292  2002-12-01 00:00:00                                              Bayer  \n",
       "293  2006-02-01 00:00:00                                              Bayer  \n",
       "\n",
       "[294 rows x 7 columns]"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "test_pull"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "ff899b45",
   "metadata": {},
   "outputs": [],
   "source": [
    "test_pull.to_csv(\"2023_03_27_clintrials_pull(ph3_only).csv\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "3d533501",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.7"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
